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METAL-ASSISTED HYDROLYSIS OF BIOLOGICAL MOLECULES

by

SARAH SHEALY CEPEDA

Under the Direction of Kathryn B. Grant

ABSTRACT

In Chapter I is a general description of novel metal complexes which hydrolytically
cleave peptides, proteins, DNA, and other biological molecules. These reagents are becoming the
more important as potential therapeutic agents. A panel of ligands was investigated for
coordination to ZrIV and other metals in groups 4, 5, and 6 to effect the greatest degree of
hydrolysis. Chapter II describes a ZrIV complex which is capable of hydrolyzing a 30 amino acid
peptide, insulin chain B, with amino acid specificity. Oxidized insulin chain B peptide was
hydrolyzed after only 4 h of treatment at pH 7.0 and 60 °C using ZrCl4 in the presence of 4,13diaza-18-crown-6. MALDI-TOF and ESI LC-MS mass spectra indicated that insulin chain B was
hydrolyzed by ZrIV at the Gly8-Ser9, Ser9-His10, and Gly20-Glu21 amide bonds within the
oligopeptide.

To our surprise, the cysteine sulfonic acid sequences Cys(SO3H)7-Gly8 and

Cys(SO3H)19-Gly20 were also cleaved. To the best of our knowledge, this constitutes the first
example of metal-assisted hydrolysis of a Cys(SO3H)-Xaa amide bond. This is significant in

light of the fact that cysteine sulfonic acid formation in proteins is triggered by oxidative stress
and has been associated with amyloid fibril formation, Parkinson’s disease, and other
deleterious, physiological processes.
Chapter III describes the metal-assisted hydrolysis of sphingomyelin which is a principle
phospholipid component of animal cell membranes. The sphingomyelin assays showed evidence
of metal-assisted hydrolysis after 20 h of treatment at lysosomal pH 4.8 and cytosolic pH 7.0 at
both physiological temperature 37 °C and 60 °C. The metal ion CeIV was the most reactive,
followed by ZrIV, and then HfIV. The goal of this work is to develop metal-based reagents to
reverse the lethal build-up of sphingomyelin that occurs in lysosomes of patients suffering from
Niemann-Pick disease.
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CHAPTER I

INTRODUCTION: METAL-ASSISTED HYDROLYSIS OF
BIOLOGICAL MOLECULES.

Hydrolysis of peptides, proteins, and lipids by metal complexes.

Synthetic metallopeptidases as proteases.
Proteases are a useful tool for protein and peptide research because of their capability to
selectively cleave proteins or peptides for sequencing, separation of proteins of interest from
fusion protein expression, proteomics, and peptide mapping. The categories of proteases
currently used include enzymatic proteases such as trypsin, chymotrypsin, and Lys-C; chemical
proteases including cyanogen bromide; and synthetic metalloproteases which are still in the
development stage. Synthetic metalloproteases are rapidly emerging as a novel protease category
because of the unique physical and chemical properties of each metal complex.1 Metal-ligand
complexes can be designed to hydrolyze the peptide amide bond. Ideally, those complexes will
rapidly cleave in high yields under mild conditions of temperature and pH, although many
synthetic metalloproteases have been demonstrated to be effective only under extreme
conditions. The ability to hydrolyze at specific amino acid residues is a key experimental
element in order to produce discrete hydrolytic products that have no oxidative and other postcleavage modifications.
Synthetic metallophospholipidases as hydrolytic agents.
Studies on the development of metal-assisted hydrolysis of phospholipids are scarce with
primary emphasis on lanthanide-assisted hydrolysis of p-nitrophenol-activated synthetic
phospholipids at the phosphate ester bond. The studies were motivated by metallonucleases
which cleave the phosphodiester bonds of RNA and DNA.2-8 The metal-assisted hydrolysis of

2

phospholipids is a potential area of therapeutic drug development with the aim of reversing the
symptoms of phospholipid accumulation in lysosomal storage diseases such as Niemann-Pick
disease and Sandhoff disease where a DNA mutation has caused lowered or negligible levels of
phospholipase activity.
Background and significance of phospholipids.
Studies of phospholipid vesicles have provided insight into the cellular membrane
environment either as models for membrane fusion or as detergent-solubilized liposomes. The
investigations into the size distributions, composition, solubilization, and penetration of small
molecules or ions have provided evidence to support a variety of mechanisms and scenarios for
diseased states.
One example of membrane composition that involves sphingomyelin is the lipid raft
which associates with certain proteins involved in cell signal pathways. Sphingomyelincholesterol domains within cellular membranes form localized distributions or cholesterolenriched microdomains called lipid membrane rafts due to the different miscibilities of
phospholipids and cholesterol which together serve as transporters of proteins, lipids, and other
second messenger molecules.9 These rafts are more resistant to Triton X-100 solubilization at 4
°C than 37 °C, and, for the lipids in the fluid state, solubilization at lower temperatures requires
less detergent, whereas, for the lipids in the gel state, solubilization at lower temperatures
requires more detergent. The rafts exist in a third state called the liquid-ordered phase.10
Under non-equilibrium conditions, the bilayers of vesicles in biomembranes have been
shown by fluorescence probe systems such as carboxyfluorescein to either leak the inner
contents or fuse into aggregates.11a-e Sphingomyelin:phosphatidyethanolamine:cholesterol (2:1:1
molar ratio) vesicles were treated with sphingomyelinase enzyme with subsequent ceramide
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production which resulted in vesicle leakage of the aqueous contents. When vesicles of the same
composition were treated with bacterial phospholipase C to produce a diacylglycerol product, the
opposite effect of vesicle fusion and aggregation occurred rather than leakage. The effects of the
enzymatic production of ceramide or diacylglyerol gives insight into the bilayer destabilization
and fusion caused by these products. Triton X-100 was used to create complete leakage and
solubilization of the bilayers.11b
The penetration of small molecules into vesicles has been simulated by studies where
fluorescent molecules such as carboxyfluorescein, N-phenyl-1-naphthylamine (NPN), 1-anilino8-naphthalene sulphonate (ANS) are entrapped inside the liposomes and therefore emit little
fluorescence. As the vesicle is solubilized due to a surfactant such as Triton X-100, the bilayer
integrity changes with subsequent release of the vesicle contents of the carboxyfluorescein. As
the contents leak out, the fluorescence increase is determined quantitatively. With ANS or NPN
probes, the interaction of the fluorescent molecules with the lipids or detergents causes a shift in
the λmax to shorter wavelengths, especially with probe-lipid bilayer interactions compared to
probe-detergent micelles interactions.11a-e
The size and shape of sphingomyelin vesicles have been studied with dynamic light
scattering, turbidity measurements, and electron or atomic force microscopy.12a-b The size
distribution of vesicles is determined because of the different biophysical characteristics that
result from the vesicle size categories. The gel to liquid-crystalline phase transition temperature
is determined by differential scanning calorimetry. Isothermal titration calorimetry has been the
main instrumentation for the study of detergent partitioning into bilayers. Considerable attention
has been given to the breakdown of lamellar structures to form lipid-surfactant mixed micelles
through the use of detergents such as Triton X-100. Optical measurements of the turbidity
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constitute a method to observe changes in vesicle size from aggregation with a turbidity increase
or from solubilization followed by decreased turbidity.
Extensive work on the solubilization of vesicles by Triton X-100 has been done to
determine the progressively complex structures that form with increasing detergent
incorporation.

11a,b,c,e

Since sonicated vesicles with entrapped drug molecules can serve as drug

carriers, the Triton X-100 detergent serves to model the changes that occur upon an encounter
with physiological amphiphiles that can also solubilize vesicles. Five stages of progressive
transformation have been described in the incorporation of Triton X-100 into vesicles to form
micelles. 12b
Background of the therapeutic use of metals.
The use of inorganic complexes in medicinal chemistry for intended biological disease
targets is an emerging field.13 The metal-ligand complexes which demonstrate no cytotoxicity
can be delivered to specific tissues, cells, or receptors. Numerous metals under investigation as
drugs include Al, Ga, In, Ti, Ru, Pt, Au, and Sn as anticancer drugs; Cu, Zn, Ag, Hg, and Bi as
antimicrobial agents; Au as an antiarthritic agent, Li as an antidepressant, Fe and Zn as
antihypertensive drugs; Li, Pt, Au, W, and Cu as antiviral drugs; Bi as an antiulcer drug, Al, Na,
Mg, and Ca as antacids; and metalloporphyrins for use in photodynamic therapy. The ions of PtII,
AuI, and BiIII are the most prevalent examples with the platinum(II) anticancer agents such as
cisplatin and carboplatin; AuI in the form of antiarthritic drugs while BiIII subcitrate and
subsalicylate serve as antiulcer drugs. The Pt drugs are known to target DNA while AuI binds
DNA very weakly, but binds cysteine-34 of serum albumin very strongly via thiolate exchange
reactions.

Under oxidative conditions of inflamed joints, AuI is oxidized to AuIII in the

lysosomes as a result of antigen processing by proteases. Using the FeIII serum transport protein
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transferrin with ruthenium and titanium incorporation, the metals are released inside cells
especially in the acidic environments such as endosomes. BismuthIII interferes with the uptake
and metabolism of FeIII used by bacterium such as Helicobacter pylori.14 By coupling metal
properties with natural biodistribution and physiological pathways, a metal complex can be
targeted to specific organelles.15
Many studies16-30 have investigated the biological fate of ZrIV in the form of
organometallic and inorganic complexes and in radioactive or non-radioactive forms in humans,
animals, or cells using several techniques especially positron emission tomography. A few trends
have been discerned, e.g., ZrIV complexed with albumin or antibodies is organ-specific and does
not accumulate in the bone. Other researchers have noted that zirconium is initially retained in
the soft tissue and then slowly accumulates in the bone. The metal is able to cross the bloodbrain barrier and the placenta. Inorganic zirconium complexes either accumulate in the bone or
are cleared by the kidneys. Zirconium species in deodorants and anti-perspirants produced
allergic responses with migration inhibitory factor and lymphocyte production and positive
antigenicity. In contrast, Zr salts acted as lymphocyte mitogens and augmented the response of
immune cells. Human peri-implant cells including fibroblasts, lymphocytes, osteoblasts-like
MG-63 cells were grown with 0.001-10 mM ZrCl4. At concentrations < 0.1 mM ZrCl4, the metal
did not reduce proliferation of the cells. Only concentrations > 1.0 mM ZrCl4 produced toxicity
to the cells.16-30
While CeIII hepatotoxicity injury has been extensively documented31a-c, a few studies
have documented cerium(IV) toxicity mainly via reaction with sulfhydryl-containing compounds
such as cysteine amino acids. CeriumIV was shown to generate thiyl free radicals in the cellular
systems containing cysteine which caused serious damage in the cell function especially the
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muscular protein myosin and the contractile protein actin from rabbit skeletal muscle with
conformational changes that affected activity such as the ATPase activity of myosin.31d
Cerium(IV) sulfate was shown to bind lactoferrin which is a metal-binding protein in the
transferrin family. The two Ce4+ ions occupied the same position in Ce2Lactoferrin as the typical
in vivo Fe2Lactoferrin.31e
An important development in metal-based drug design are metallocene complexes with
transition metals which have demonstrated antitumor effects with antiproliferative properties.32-35
Metallocenes are neutral complexes of distorted tetrahedral coordination geometry of two h5cyclopentadienyl rings between transition metal such as Ti, V, and Zr. Titanocene has been used
unsuccessfully in Phase 2 clinical trials. The dichlorides are the most common metallocenes and
represented by formula (Cp)2MCl2 where M is metal and Cp is the cyclopentadienyl group. The
metallocenes are ionic and cationic salts without halides. The anion is usually trichloroacetate,
picrate, or tetrahalideferrate (III). The largest use of organozirconium compounds is as
polymerization catalysts for ethylene polymerization and for transition-metal-catalyzed crosscouplings. A related zirconocene compound is Schwartz Reagent (Cp2ZrHCl) which has been
used for hydrozirconation in the production of antiestrogen drugs.32-35
Zirconium is nontoxic, unlike some other transition metals, so its use as a metallocene
therapeutic agent merits further exploration. The lack of cytotoxicity of the zirconocene was
noted in a study where zirconocene was combined with adriamycin for therapeutic
investigations, although, the ZrIV-adriamycin complex was devoid of antitumor activity.36 The
titanium metallocenes have shown strong antiproliferative activity against fluid Ehrlich ascites
tumor, solid B16 melanoma, colon 38 adenocircoma, and Lewis lung carcinoma cell lines. The
metallocenes (Cp2MX2) are generally believed to effect inhibition of nucleic acid metabolism,
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mitotic activity, as well as accumulate in the nuclear heterochromatin of the tumor cells.35,37a-b
In nude mice studies, metallocenes showed antiproliferative effects against implanted human
tumors. Comparisons of titanocene dichloride and dibromides to 5-fluorouracil showed similar
efficacies. Substitution of the cyclopentadienyl groups reduces tumor inhibition substantially.32
Mechanistic studies of peptides.
Transition metal ions and complexes have been investigated for their catalytic ability to
hydrolyze the polypeptide backbone under various conditions of temperature and pH. Unlike
oxidative cleavage in which the peptide backbone α-carbon hydrogen atoms are abstracted by
metal-generated hydroxyl radicals to produce multiple, fragmented peptide products, the
hydrolysis of peptides involves addition of water across the amide bond in the backbone
followed by release of two hydrolyzed, native peptides with free N-terminal and C-terminal
groups as shown in Figure 1.1. The metal-assisted hydrolysis of the peptide would yield products
which are comparable to natural metal-activated peptidase reactions.
The proposed role of proteolytic metals ions in promoting hydrolytic reactions in peptides
may include molecular scaffolding for proper juxtaposition of a hydroxide nucleophile to the
substrate, direct activation of the carbonyl bond by a free metal ion, charge neutralization and
stabilization of the negatively-charged tetrahedral intermediate formed by coordination of the
metal’s electropositive charge to a negatively charged carbonyl oxygen, and/or serve as a metalhydroxide nucleophile at neutral pH where many metals exist as a hydroxide complex due to the
deprotonation of the waters of hydration. Four proposed schemes for mechanisms of the peptide
hydrolysis are shown in Figure 1.2. A tetrahedral intermediate is formed in all cases.1,3 Scheme I
shows the direct coordination of the metal to the carbonyl oxygen while a hydroxide nucleophile
from the aqueous solution adds to the carbonyl carbon. In Scheme II, a metal-coordinated
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hydroxide species which is generated by deprotonation of a metal-bound water of hydration,
adds a hydroxide group to the carbonyl. Scheme III involves a multiple coordination of a
hydroxide nucleophile and the amide bond’s carbonyl oxygen while the attached hydroxide
nucleophile adds to the carbonyl carbon. The ZrIV metal used in the studies described in this
dissertation is oxophilic and forms complexes with a high coordination numbers such as the
coordination of both the amide carbonyl oxygen and the hydroxide group that Scheme III entails.
Scheme IV is a variation of Scheme III where the metal-hydroxide species activates the carbonyl
oxygen, and the coordinated hydroxide acts as a base toward another acidic water molecule in
solution whose deprotonated hydroxide nucleophilic species then attacks the amide carbonyl
carbon. The proposed tetrahedral intermediate in schemes I, II, and III forms a metal-coordinated
intermediate whose RNH- M+ leaving group may not be labile and may form a hydrolytically
inactive species. However, Scheme IV involves protonation of the RNH- group by the metalbound water of hydration in an acid-base reaction to form a more labile RNH2 leaving group.
Aqueous speciation of certain metals.
When strong Lewis acid metals are bound by waters of hydration in aqueous solutions,
the metals often lower the pKa of the attached waters from 15.7 to lower, acidic pKa values. For
example, the pKa of metal-bound water molecules are ≤ 1 for ZrIV, HfIV, and CeIV so that the
concentration of metal-hydroxide nucleophiles from the deprotonated water bound metal are
abundant at neutral and mildly acidic pH values. The precise aqueous speciations of ZrIV, HfIV,
and CeIV are not known, although ZrIVaq equilibrates at low pH as [Zr4(OH)8(H20)16Cl6]2+
(tetranuclear ion) and [Zr8(OH)20(H2O)24Cl12] + 4H+ + 4H2O (octanuclear ion). At higher pH
values, these ZrIV aqueous complexes speciate to form insoluble gels and precipitates.37
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Figure 1.1. The hydrolysis of the peptide bond to yield two intact peptides.1

Figure 1.2. Four proposed mechanisms leading to a tetrahedral intermediate in metal-assisted
peptide hydrolysis.1

10

Figure 1.3. The PdII-assisted coordination with a histidine residue in an X-Y-His peptide
sequence. In weakly acidic solutions, the PdII reagent cleaves the second peptide bond upstream
from the anchoring histidine residues.40h
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The aqueous speciation of CeIV above pH 4 results in the formation of insoluble CeIV-hydroxide
gels. The dimeric CeIV-hydroxo species [CeIV2(OH)4]4+ is attributed to be the reactive entity in
several studies.4b,39aBackground and significance of metal-assisted hydrolysis of peptides.
Transition metals.
Metal ions and complexes of CeIV, CoII, CeII, CuII, MoIV, NiII, PdII, PtII, ZnII, and ZrIV
have been used to hydrolyze peptide bonds.1,39-43 For CuII, CoIII, NiII, PdII, and PtII, large proteins
and peptides have been cleaved. An example is the PdII hydrolysis of methionine enkephalin at a
–G|X-H bond after 1-2 days at 60 °C, and pH 0.5.40e Figure 1.3 illustrates the PdII-assisted
coordination with a histidine residue in an X-Y-His peptide sequence. In weakly acidic solutions,
the PdII reagent cleaves the second peptide bond upstream from the anchoring histidine
residues.40h Another example is the CuII hydrolysis of insulin chain B at a –G|S-H bond after 4 h
at 25 °C, and pH 2.5.40f NiII hydrolyzed a histone peptide at the –E|S-H bond after 134 h at 37
°C, and pH 7.4.40g While some metals demonstrate unique specificities and good hydrolytic
yields, only a few of the reaction conditions cited in the literature are at non-denaturing pH and
temperature. The synthetic metalloprotease preference is for hydrolytic metal complexes with
unique specificities toward certain amino acids, that can not only developed as catalytic agents
that cleave under physiological conditions, but also as proteolytic tools for protein structural
elucidation by mild proteolysis where the tertiary and quaternary protein structures are not
disturbed. The ZrCl4 salt in the presence of 4,13-diaza-18-crown-6 was used by our research
group to hydrolyze an extensive series of dipeptides to determine the ZrIV specificity toward
amino acid residues.

ZrIV showed a distinct preference for hydrolysis of dipeptides with

negatively charged and oxygen-containing sidechains as determined by LC colorimetric
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techniques.43

Using this information, we then wanted to adapt this same ZrIV/ 4,13-diaza-18-

crown-6 complex to hydrolyze larger peptides and proteins and to study the products using mass
spectral techniques of matrix-assisted laser desorption ionization (MALDI) and high
performance liquid chromatography electrospray mass spectrometry (HPLC-ESI-MS), which
allow not only unequivocal determination of molecular weight, but also subsequent confirmation
of hydrolysis products by tandem mass spectrometry (MS/MS) analysis.
Zirconium(IV).
As mentioned previously, transition metal complexes that efficiently hydrolyze peptides
under non-denaturing conditions of pH and temperature represent an emerging area of research.
Zirconium(IV), a transition metal ion with a [Kr] ground state configuration, has been the major
emphasis of our metallopeptidase investigations because of its strong Lewis acid strength, fast
ligand exchange kinetics, redox inactive state, and its oxophilic characteristics as summarized in
Table 1.1. Zirconium(IV) in the presence of 4,13-diaza-18-crown-6 has outstanding proteolytic
ability at pH 7.0 and 60 °C with a selectivity toward peptide amide bonds in dipeptides with
negatively-charged, oxygen amino acid side chains.1,43 Consequently, ligands with similar
structures to or substructures of the 4,13-diaza-18-crown-6 have been investigated by our
laboratory as possible ZrIV complexes. Because of mild experimental conditions of pH and
temperature employed, several of the ZrIV complexes showed promise for future use in the study
of protein solution structure, the generation of semi-synthetic proteins, the proteolytic cleavage
of bioengineered fusion proteins, and therapeutics.
Our first aim in the ZrIV-assisted hydrolysis of peptides was to apply the same ZrIV-4,13diaza-18-crown-6 complex used in our preliminary dipeptide studies43 to larger peptides and
proteins and to use different detection techniques to study reaction products especially mass
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Table 1.1. Properties of zirconium(IV).

Zirconium(IV) Properties
Lowers the pKa of bound water from 15.7 to ≤ 0.6
Redox inactive (do electron configuration)
Stable +4 oxidation state
Complexes have high coordination number
Oxophilic
Hydrolyzes phosphodiester bonds
Strong Lewis acids
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spectrometry ionization techniques. An initial study of metal-assisted hydrolysis of oxidized
insulin chain B, from the biologically active insulin peptide hormone that regulates the cellular
uptake, utilization, and storage of glucose, amino acids, and fatty acids, was undertaken.
As described in Chapter II, our data demonstrates that ZrIV is capable of hydrolyzing insulin
chain B in a sequence specific fashion after only 4 h of treatment at 60 °C and pH 7.
Background and significance of metal-assisted hydrolysis of phospholipids.
Under normal conditions, most phospholipids are metabolized in the acidic lysosomes of
cells that contain lipases and other hydrolytic enzymes.45-46 Many inherited phospholipid-related
disorders are the result of the accumulation of specific unmetabolized phospholipids with
manifestation of clinical symptoms due to decreased activity of a defective hydrolytic enzyme.
The disorders associated with defective lysosomal enzymes are categorized as lysosomal storage
diseases or LSDs and include more than forty diseases resulting from chromosomal mutations.
Examples include Niemann-Pick disease types A and B where defective acid sphingomyelinase
causes sphingomyelin and associated cholesterol accumulation in lysosomes.

In Gaucher’s

disease, glucocerobroside accumulates from the lack of metabolism due to a defective
glucocerobrosidase enzyme. Fabry’s disease results from a deficiency of the enzyme alpha
galactosidase

A

which

normally

metabolizes

a

glycosphingolipid

known

as

globotriaosylceramide or Gb3.47
Mechanistic studies of metal-assisted phosphate ester bond hydrolysis.
Mechanistic studies on phosphate ester hydrolysis of phospholipids are scarce. The Lewis
acids of ZrIV, HfIV, and CeIV are classified as hard acids and oxophilic so that the metals are
capable of activating a phosphate ester bond towards nucleophilic attack by charge neutralization
and the provision of metal-bound hydroxides due to their ability to lower the pKa of the bound
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waters of hydration.48-49 Metal-assisted catalysis of the activated phosphate ester bond in bis(pnitrophenyl)-phosphate or BNPP which is a model for DNA phosphodiester linkage has been
studied to compare the rates of hydrolysis by various metals of which the lanthanide metals,
especially the highly reactive CeIV, have the highest rates.6

The CeIV ion, as cerium(IV)

ammonium nitrate was fifty times more reactive than other lanthanides such as EuIII, LaIII, or PrIII
in a Brij-induced micellar preparation of BNPP.6 Other applications of metal-assisted catalysis
have been applied as nucleases toward phosphate ester hydrolysis with RNA more susceptible to
hydrolysis than DNA. ZrIV was shown to hydrolyze bis(p-nitrophenyl)phosphate in a pH
dependent fashion as well as CeIV with maximum reactivity at pH 4. In the same study, ZrIV (5
mM) salt hydrolyzed the phosphodiester linkage in the DNA dinucleotide thymidylyl (3′→5′)
thymidine in the presence of 10 mM Tris at pH 5.5 and 20 °C at a rate with a half-life of 28
days.2
Summary of mechanisms.
The general agreement about the mechanism of metal-assisted cleavage of the phosphate
ester bonds in lipids is that the positively-charged metal binds and partially neutralizes the
negatively-charged P-O- oxygen while activating and polarizing the substrate for nucleophilic
attack by the metal’s attached hydroxyl nucleophile (M-OH) which attacks the phosphate group
of the P=O functional group. Figure 1.4 shows an example of this mechanism with the
Cu([9]aneN3)Cl2-assisted hydrolysis of an activated phosphate ester. The transition state and
intermediates show the intramolecular nucleophilic attack by the metal-bound hydroxide.50
Lanthanide ions LaIII, EuIII, and LuIII were used in modeling RNA cleavage and catalysis
via phosphate diester transesterification by studying the amount of released 4-nitrophenol from
4-nitrophenolphosphate esters of propylene glycol following lanthanide- assisted hydrolysis. The
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pH-rate profiles showed that the lanthanide hydroxide species [Ln(OH)2+] is the active catalyst
and serves as a general base where two coordination sites are required for binding of both a
hydroxide and a phosphate ester. The pseudo-first-order rate constants showed a pH dependence
of increasing kobs with increasing pH and a maximum rate in the pH range 8.5-9.51
Figure 1.5 shows a proposed schematic of the ZrIV hydrolysis of the sphingomyelin
phospholipid with a Zr-OH bound transition state to release choline and a phosphoceramide. The
release of choline is one of two possible pathways of ZrIV hydrolysis. The release of
phosphocholine is the physiological pathway.
Significance of metal-assisted hydrolysis of sphingomyelin.
Niemann-Pick disease is an incurable, autosomal recessive, lysosomal storage disorder
with two phenotypes A and B.52 Type A primarily affects Ashkenazic Jews with infant mortality
while type B affects other diverse ethnic groups with middle age mortality. The defective
enzyme acid sphingomyelinase has only 1-3% normal activity in type A while type B has 10 60% of normal enzyme activity resulting in fatal accumulation of sphingomyelin in the
lysosomes. The affected organs in type A are the spleen, lymph nodes’ monocyte-macrophage
system, liver, kidneys, brain, and lung, while type B has similar patterns except for no
accumulation in the brain. Cholesterol also builds up in the lysosomes, most probably due to the
interdispersion of cholesterol with sphingomyelin in the periplasmic membrane. Enzyme
replacement and chemical chaperones have had limited therapeutic success in Niemann-Pick
patients. A novel therapeutic cure based on ZrIV-assisted phospholipid hydrolysis is a developing
concept in our laboratory to decrease this fatal accumulation of the sphingomyelin. Since ZrIV is
redox-inactive and possesses low cellular toxicity, a ZrIV complex which efficiently
hydrolyzessphingomyelin at the same hydrolytic bonds as the acid sphingomyelinase enzyme
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Figure 1.4. Proposed mechanism of the Cu([9]aneN3)Cl2-assisted hydrolysis of an activated
phosphate ester showing the transition state and intermediates.50
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Amorphous ZrIV ppt.
+ sphingomyelin

Zr-OH binds to the
phosphate of
sphingomyelin

Transition state with
ZrIV activation of the
phosphate group and
OH nucleophilic
attack.
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and choline
products and
amorphous ZrIV
ppt.

Figure 1.5. Proposed schematic of the ZrIV hydrolysis of sphingomyelin with a Zr-OH bound
transition state to release choline and a phosphoceramide.
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may function as an enzymatic mimic. It is worthwhile to investigate the pH-dependent
reactivities of metals to determine the increase in metal-assisted hydrolytic cleavage in the
lysosomes compared to cytosol. Several rat studies have shown that zirconium(IV) is localized in
the lysosomes upon ingestion which suggests a possible therapeutic ability to target the diseased
organelle. Electron probe x-ray microanalysis of thin tissue sections from rat have shown that
ingested ZrIV plus HfIV and CeIV accumulates in the lysosomes as a phosphorus complex
probably due to the activity of acid phosphatase.54a

Zirconium(IV), injected as zirconium

sulfate, localized in the lysosomes of the lymph node macrophages as a phosphorus complex.54b
The optimal hydrolysis of DNA and acetylated peptides by ZrIV has been shown to be higher at
(lysosomal) pH 4.8 than (cytosol) pH 7.0.2,53 A proposed mechanism for the ZrIV-assisted
hydrolysis of sphingomyelin to release choline and a phosphoceramide is shown in Figure 1.5.
Hydrolysis could likely occur on the other side of the phosphate ester bond to release
phosphocholine and ceramide which is similar to the in vivo enzymatic reaction. The presence of
the Triton X-100 compound, used in our studies for solubilization purposes, has been applied
therapeutically to the encapsulation of biodegradable nanoparticles with drugs since the
surfactact stabilizes the polymer particles during the microencapsulation process.55a-b
Research objectives.
In Chapter II of this dissertation, our research goals were to design and evaluate ZrIV
complexes which hydrolyze the amide bond of peptides and proteins with amino acid residue
specificity. We have demonstrated the proteomic capabilities of the ZrIV-assisted hydrolysis of
larger biological proteins by mass spectral data and determined post-reaction side modifications
to the protein or its products. We found that the ZrIV in the presence of 4,13 diaza-18-crown-6
hydrolyzes not only a Gly-Glu amide bond, but also the oxidized cysteine sulfonic acid residues
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in the insulin chain B protein. Clinically, these oxophilic ZrIV complexes can perhaps be
developed to target specific disease-related proteins that have irreversible oxidation especially
cysteine oxidation in order to prevent cellular accumulation.
In Chapter III of this dissertation, our aim was to expand the studies of ZrIV complexes
with comparison to other metals to observe the hydrolysis of an unexplored class of molecules of
phospholipids, namely sphingomyelin. To the best of our knowledge, we are the first to present
the metal-assisted hydrolysis of sphingomyelin. The impact of this research is the development
of therapeutic applications to Niemann-Pick diseases type A and B which exhibits fatal
symptoms due to the accumulation of sphingomyelin in the lysosomes. We found that the
tetravalent metals ZrIV, CeIV, and HfIV efficiently hydrolyzed sphingomyelin in good yields as
quantified by an Amplex Red and inorganic phosphate assays. The effects of Triton X-100 and
cholesterol on the hydrolysis of sphingomyelin were investigated.
The conclusions of the contributions of the metal-assisted hydrolysis of two classes of
biological molecules including proteins and phospholipids are presented in Chapter IV. The
specific hydrolytic capabilities of certain metals to mimic enzymatic reactions that are defective
in diseased states represents progress in an emerging research area.
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CHAPTER II

HYDROLYSIS OF INSULIN CHAIN B USING ZIRCONIUM(IV) AT
NEUTRAL PH.

(This chapter is taken verbatim from an article by Sarah S. Cepeda and Kathryn B. Grant, New
Journal of Chemistry, 2008, 32, 388-391. Sarah S. Cepeda conducted the experiments and
contributed to the writing of the article. The final version of the manuscript was written by Prof.
Kathryn B. Grant. Following the chapter is an unpublished epilogue showing additional data)

Abstract.

Zirconium(IV) hydrolyzes the 30-mer oligopeptide oxidized bovine insulin chain B after
4 h to 8 h of treatment at pH 7.0 and 60 °C: MALDI-TOF and HPLC-ESI-MS and MS/MS data
show significant levels of cleavage at Gly8-Ser9, Gly20-Glu21, Ser9-His10, Cys(SO3H)7-Gly8,
and Cys(SO3H)19-Gly20 amide bonds within the oligopeptide.
Introduction.
There has been widespread interest in the development of metal complexes that
hydrolyze peptide amide bonds under mild conditions of pH and temperature.1

These

compounds are of great importance due to their potential applications in the analysis of protein
solution structure, in protein engineering, and in therapeutics.1d,f,h,2 Our own research efforts
have primarily focused on zirconium (IV). Because of its enhanced Lewis acid strength,
oxophilicity,3 tendency to form complexes with high coordination numbers,3 and rapid ligandexchange kinetics,4 this metal center should be able to catalyze peptide hydrolysis by activating
an amide carbonyl carbon in the peptide backbone while delivering a hydroxide nucleophile to
the scissile amide bond.1f Recent efforts in our laboratory have demonstrated that ZrIV in the
presence 4,13-diaza-18-crown-6 has excellent reactivity: t1/2 values are 5.3 ≤ 0.1 h and 36.6 ≤ 2.7
h for ZrIV-assisted hydrolysis of the dipeptide Gly-Glu at pH 7.1/60°C and at pH 7.3/37°C.1f
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(These half-lives represent significant rate enhancements compared to the t1/2 of ~250 years for
spontaneous hydrolysis of unactivated peptide amide bonds at pH 7.0 and 37°C).5 The formation
of insoluble ZrIV precipitates during the cleavage reactions led us to speculated that hydrolysis of
peptides by ZrIV/4,13-diaza-18-crown-6 might have a heterogeneous component similar to
peptide hydrolysis by lanthanide hydroxide gels.6 Yet, in spite of the attributes of ZrIV, the
largest peptide to have been hydrolyzed by this metal center was Ala-Gly-Asp-Val.1f To address
this size limitation, herein we report efficient, ZrIV-assisted hydrolysis of the 30-mer
oligopeptides oxidized bovine insulin chain B.
Results and discussion.
In a typical cleavage reaction, 500 uM to 1 mM of oxidized bovine insulin chain B was
added to 20 mM of 4,13-diaza-18-crown-67 in the presence or absence of 10 mM of ZrCl4.
Hydrolysis reactions were allowed to proceed at pH 6.9-7.2 and 60°C. Aliquots were removed at
~t = 0 h, 4 h, and 8 h time points, quenched with the strong chelating agent EDTA, and then
analyzed by HPLC-electrospray ionization mass spectrometry (ESI-MS) or by matrix-assisted
laser desorption ionization time-of-flight (MALDI-TOF) MS. Mass spectral peak assignments of
peptide hydrolysis products were made using FindPept software and ESI tandem mass
spectrometry (MS/MS) (Figure 2.1(a) and (b)). Each of the peptide fragments produced by
ZrIV/4,13-diaza-18-crown-6 was defined as either an apparent major, intermediate, or trace
product depending on its percent relative abundance in the HPLC-ESI chromatograms and
MALDI-TOF mass spectra. In Figure 2.1(c) is the primary amino acid sequence of insulin chain
B showing the positions of peptide amide bond hydrolysis indicated by the MS data. In addition
to percent relative abundance, Tables 2.1 and 2.2 summarize observed vs. calculated m/z values.
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The HPLC-ESI chromatograms and MALDI-TOF mass spectra in Figure 2.2 and Figure
2.3 reveal the time-dependent appearance of prominent insulin chain B peptide hydrolysis
products B, C, D, E, F, G, I, K, K‡, L, W, and X. It is evident that shorter peptide fragments B,
D, F, I, K, K‡, L, W, and X become more dominant as the reaction proceeds from t = 4 h to t = 8
h, while the larger fragments C, E, G are prominent only at t = 4 h (Figure 2.2).
The cleavage yields corresponding to the HPLC-ESI chromatograms shown in Figure 2.2
were estimated by taking the sum of the peak areas of all the peptide hydrolysis products,
dividing this sum by the total peak areas of the peptide hydrolysis products added to the peak
area of any remaining unhydrolyzed peptide, and then multiplying the quotient by 100:
hydrolysis yield = [sum of all peptide hydrolysis product peak areas / (sum of all peptide
hydrolysis product peak areas + unhydrolyzed insulin chain B peak area)] x 100. In the
presence of ZrIV/4,13-diaza-18-crown-6, these values were 0% at t = 0 h, 15 % at t=4 h and 51 %
at t = 8 h (pH 7.0 and 60 °C). In parallel control reactions in which ZrCl4 was substituted by
equivalent volumes of water, corresponding values were minimal (0 % at t=0 h, 0 % at t=4 h and
3 % at t= 8 h).
As expected, a larger number of peptide fragments was detected by HPLC-ESI-MS in
comparison to MALDI-TOF MS. (In complex mixtures of analytes, competition for charge can
lead to ion suppression. As a result, pre-separation is often needed to enhance sensitivity).8
Notwithstanding, the MALDI and HPLC-ESI experiments are in good general agreement (Figure
2.1, 2.2, 2.3). The data collectively indicate that ZrIV/4,13-diaza-18-crown-6 produces major
amounts of hydrolysis at the following five amide bonds: Gly8-Ser9, Gly20-Glu21, Ser9-His10,
Cys(SO3H)7-Gly8, and Cys(SO3H)19-Gly20. With respect to Gly8-Ser9, cleavage of XaaSer(Thr) in peptides and proteins containing the sequence Xaa-Ser(Thr)-His has been extensively
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documented for CuII,2b,9a,b,e,f NiII,1b and PdII,

9b-d

and is thought to involve an N→O acyl

rearrangement promoted by the hydroxyl group side chains of serine or threonine.1b,9a,d We also
expected to observe significant levels of hydrolysis at Gly20-Glu21 and at Ser9-His10.

In a

previously published report, we demonstrated that ZrIV/4,13-diaza-18-crown-6 displays a clear
preference for hydrolysis of neutral and negatively charged peptides containing glycine or amino
acids with oxygen-rich side chains.1f (In fact, Gly-Glu was the most reactive of the 16 dipeptides
studied.)

The oxophilicity of ZrIV combined with electrostatic interactions between this

positively charged metal center and negatively charged Cys(SO3-) could account for the efficient
hydrolysis of the Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20 amide bonds in bovine insulin
chain B. In addition to the five major products, ZrIV/4,13-diaza-18-crown-6 produced apparent
intermediate amounts of hydrolysis at: Leu6-Cys(SO3H)7, Arg22-Gly23, and Gly23-Phe24.
This pattern again may reflect the preference of ZrIV for hydrolysis of peptides with glycine or
oxygen-rich side chains. As shown in Figure 2.1 and Tables 2.1 (in ESI), trace amounts of
hydrolysis were seen at five sites within the oligopeptides.
Up until now, hydrolysis of oxidized insulin chain B has been studied using salts and/or
complexes of CuII,9b,g PdII,9b,c PtII,9g and ZnII 9h. These experiments were conducted under acidic
conditions (pH 2.0 to 2.5) at temperatures ranging from 40 °C to 60 °C. Hydrolysis reactions
were studied by ESI-MS,9b,g,h HPLC-ESI-MS,9g MS/MS,9g,h and MALDI-TOF MS.9c The data
showed that metal binding sites included the N-terminal amino group of Phe1 (CuII, PdII, and
PtII),9b,c,g the imidazole side chains of His5 and His10 (CuII, PdII, PtII, and ZnII), 9b,c,g,h and Arg22
(ZnII).9h If the metal-peptide complexes formed were hydrolytically active, then amide bond
hydrolysis occurred in close proximity to the anchoring amino acid residue. Thus, the following
insulin chain B peptide amide bonds were hydrolyzed: Phe1-Val2 (CuII),9g Asn3-Gln4 (CuII, PdII,
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Figure 2.1. Peptides detected in (a) HPLC-ESI and (b) MALDI-TOF mass spectra. The colors
blue, red, and green identify apparent major, intermediate, and trace hydrolysis products,
respectively. “†” = deamidation of Asn3 to Asp3, and/or Gln4 to Glu4. “‡” = lactamization of
Glu21 to pyroglutamate21 (pyroGlu21). (c) Corresponding ZrIV/4,13-diaza-18-crown-6 cleavage
sites superimposed on the amino acid sequence of oxidized bovine insulin chain B.
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Figure 2.2. HPLC chromatograms of 500 µM of insulin chain B treated with 10 mM ZrCl4 in 20
mM 4,13-diaza-18-crown-6 for t = (a) 0 h, (b) 4 h, and (c) 8 h (pH 7.0 and 60 °C). Peak A is
unhydrolyzed insulin chain B. Peaks B, D, F, I, K, and peaks L, X, W, K‡, C, E, G correspond to
apparent major and intermediate peptide hydrolysis products, respectively. Trace hydrolysis
products are in Table 2.1 (in ESI). Representative ESI mass spectra are in Figure 2.4 to 2.6
“Crown” identifies the azacrown ether. “*” identifies Na-adducted monomer and Na-adducted
cluster dimers of peak A.
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Figure 2.3. Representative MALDI-TOF mass spectra for hydrolysis of 1 mM of insulin chain B
at (a) t = 0 h and (b) t = 4.2 h. Reactions were run in 10 mM ZrCl4 and 20 mM 4,13-diaza-18crown-6 at pH 7.2 and 60 °C. Peak A is unhydrolyzed insulin chain B. Peaks K‡ and E and
peaks I, G, and C correspond to apparent major and intermediate peptide hydrolysis products,
respectively. Trace hydrolysis products are listed in Table 2.2 (in MALDI). Human angiotensin
I is the internal standard. All masses are singly charged unless otherwise indicated.
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ZnII),9c,g,h His5-Leu6 (ZnII),9h Gly8-Ser9 (CuII, PdII, ZnII),9c,g,h His10-Leu11 (PtII),9g and Glu21Arg22 (ZnII).9h In urea-denatured oxidized hog insulin chain B, PdII produced cleavage at Leu6Cys(SO3H)7 and at Gly8-Ser9.9b,10 Because no other cleavage sites were observed in any of the
MS studies,9b,c,g,h the hydrolysis of Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20 amide bonds by
ZrIV-4,13-diaza-18-crown-6 points to unprecedented cleavage of insulin chain B at
approximately neutral pH.
Metal salts of CeIII, CeIV, LaIII, ThIV, and ZrIV accelerate the lactamization of glutamate
(Glu) to pyroglutamate (pyroGlu) at 70 °C over a weakly acidic to weakly alkaline pH range.11
As shown in Figure 2.2 and Figure 2.3, ZrIV-assisted hydrolysis of oxidized bovine insulin chain
B produces peptide fragment K (Glu21 to Ala30, m/z 1216) and a second prominent peptide K‡
(pyroGlu21 to Ala30, m/z 1198). We attributed the appearance of the latter fragment to loss of
water through lactamization of the N-terminal glutamate residue in peptide K. Pyroglutamate
formation was confirmed by ESI-MS/MS of K‡ which produced a pyroGlu immonium ion at m/z
84.2. In addition to lactamization of glutamate, CeIII, CeIV, LaIII, ThIV, and ZrIV ions accelerate
the hydrolytic deamidation of glutamine and asparagines residues.12 In our experiments, HPLCESI analyses of the ZrIV reactions detected the production of apparent trace quantities of the
following three sets of insulin chain B peptides: B†(1) and B†(2); D†(1) and D†(2); and F†(1)
and F†(2) (Table 2.1. in ESI). We then employed ESI-MS/MS sequencing to show that these
fragments were produced by deamidation of parent peptides B, D, and F; in B†(1), D†(1), and
F†(1), Gln4 in the corresponding parent was converted to Glu4; in B†(2), D†(2), and F†(2),
Asn3 and Gln4 were deamidated to Asp3 and Glu4 (Figure 2.7). Interestingly, deamidation of
glutaminyl and asparaginyl residues occurs in vivo. Because a correlation exits between protein
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lifetime and total amide content, it has been suggested that deamidation may play a physiological
role in triggering protein degradation.13
Up until now, the largest peptide to have been hydrolyzed by zirconium(IV) consisted of
only four amino acid residues.1f We have successfully addressed this apparent limitation in the
present study. By using HPLC-ESI-MS and MS/MS, and MALDI-TOF MS, we have
demonstrated that ZrIV/4,13-diaza-18-crown-6 facilitates hydrolysis of the 30-mer oligopeptides
oxidized bovine insulin chain B at pH 7.0 and 60 °C. Apparent major levels of cleavage were
produced at Gly8-Ser9, Gly20-Glu21, Ser9-His10, Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20
sequences, while intermediate amounts of hydrolysis were at Leu6-Cys(SO3H)7, Arg22-Gly23,
and Gly23-Phe24, ZrIV/4,13-diaza-18-crown-6 was also shown to promote lactamization of Nterminal Glu21 and deamidation of Asn3 and Gln4. To the best of our knowledge, this paper
presents the first example of metal-assisted hydrolysis of a Cys(SO3H)-Xaa peptide amide bond.
This is significant in light of the fact that the formation of cysteine sulfonic acid in proteins is
triggered by oxidative stress and has been associated with amyloid fibril formation, Parkinson’s
disease, and physiological processes involving oxidative stress response proteins.14 Our current
work is focused on mechanistic studies that should enable us to design new zirconium ligands
that optimize sequence specificity and increase the hydrolytic efficiency of ZrIV.
We thank the National Science Foundation for financial support under grant CHE0718634.
Experimental.
Peptide hydrolysis reactions. A total of 500 µM to 1 mM of oxidized bovine insulin
chain B (freshly dissolved in doubly distilled H2O) was added to 20 mM of 4,13-diaza-18crown-6 in the presence or absence of 10 mM of ZrCl4 (400 µL total volume). The pH value of
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the zirconium solution was adjusted at 25 °C to 6.9-7.2 by addition of the azacrown ether.7
(Alternatively, in the absence of ZrCl4, pH was adjusted with HCl.) Hydrolysis reactions wre
then allowed to proceed at 60 °C and aliquots were removed at ~ t = 0 h, 4 h, and 8 h time points.
Pre- and post-reaction pH measurements varied by only ≤ 0.12 units.

The aliquots were

quenched at 4 °C with 1/10 volume of 0.5 M EDTA pH 8, and then analyzed by HPLC-ESI-MS
or by MALDI-TOF MS. Each of the peptide fragments produced by ZrIV/4,13-diaza-18-crown-6
was arbitrarily defined as either an apparent major, intermediate, or trace product depending on
its percent relative abundance in the HPLC-ESI chromatograms recorded at t = 4 h or t = 8 h
(Table 2.1 in ESI) and in MALDI-TOF mass spectra recorded at t = 4.2 h (Table 2.2): 44 % to
100 % for apparent major hydrolysis products, 12 % to 30 % for apparent intermediate
hydrolysis products, 1 % to 5 % for apparent trace hydrolysis products.
Mass spectrometry.
HPLC-ESI-MS

and

HPLC-ESI-MS/MS.

HPLC-ESI

chromatograms

and

corresponding mass spectra were acquired over a scanning mass range of m/z 100 to 3000 on a
Micromass Q-Tof Micro mass spectrometer equipped with a Waters 2695 HPLC. Hydrolysis
reactions were diluted 10-fold with doubly distilled H2O. A 20 µL amount of each diluted
solution was injected into a Waters Atlantis dC18 3 um, 100Å, 2.1 mm x 150 mm reversedphase HPLC column. Separations were conducted over 109 min at 20 °C with a flow rate of 0.2
mL min-1 and a mobile phase gradient elution scheme consisting of 2 % to 98 % of acetonitrile in
0.1 % formic acid. The ESI instrument settings were: electrospray needle voltage, + 3.0 kV; N2
cone gas flow, 60 L h-1; N2 desolvation gas flow, 450 L h-1; capillary desolvation temperature,
200 °C. Spectra were acquired in positive ion mode (Figure 2.4, 2.5, 2.6, 2.7,) or in negative ion
mode (Figure 2.8) with a scan time of 1.0 s.
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HPLC-ESI-MS/MS sequencing of peptide fragments was done on the Micromass Q-Tof
Micro mass spectrometer with data-directed acquisition (DDA). The MS to MS/MS switch
criteria allowed a precursor selection of a maximum of 4 concurrent ions when the ion intensity
was above a threshold of 10 ion counts per second. To induce collisional activation, the collision
energy was set at 25 V and argon was used as a collision gas at a pressure of 28 psi.
MALDI-TOF MS. To prepare the CHCA matrix, a total of 10 mg of α-cyano-4hydroxycinnamic acid was dissolved in 1 mL of water-acetonitrile (50 : 50, v/v) containing 0.1%
trifluoroacetic acid. A total of 5 µL of the matrix was mixed with 5 µL of a ten-fold dilution of
the peptide hydrolysis reaction and with 1 µL of an internal standard (1.5 uM human synthetic
angiotensin I). A total of 1 µL of the resulting solution was transferred to a MALDI sample
stage and air-dried. Positive ion MALDI-TOF mass spectra were then acquired using an Applied
Biosystems Voyager-DE PRO Biospectrometry instrument in reflectron mode. Following timedelayed extraction, ions were accelerated to 20 kV. A total of 500 laser shots was averaged for
each mass spectrum. The nitrogen laser source parameters included a grid voltage of 68.2%, a
guide wire voltage of 0.001%, and a delay time of 50 ns. The average difference between
calculated and observed mass values was m/z 0.044 ≤ 0.061.
Software. All mass spectral peptide hydrolysis product peak assignments were made
using

FindPept

software

(The

http://ca.expasy.org/tools/findpept.html).

Swiss

Institute

of

Bioinformatics;

The majority of the peak assignments was

subsequently confirmed by HPLC-ESI-MS/MS sequencing (Tables 2.1 and 2.2). Isotope
distribution patterns were predicted using the “Isotope Distribution Calculator and Mass Spec
Plotter” (Scientific Instrument Services, Inc.; http://www2.sisweb.com/mstools/isotope.htm).
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MS/MS fragmentation patterns were predicted with MassLynx/Biolynx software, version 4.0
(Micromass).
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Supporting information.

Additional experimental details.
Materials. Distilled, deionized water was utilized in the preparation of all buffers and all
aqueous reactions. Chemicals were of the highest available purity and were used without further
purification. L-glutamic acid, α-cyano-4-hydroxycinnamic acid (CHCA), human synthetic
angiotensin I, and oxidized bovine insulin chain B were purchased from Sigma.
Ethylenediaminetetraacetic acid disodium salt (EDTA) was from Fisher Scientific and HPLC
grade acetonitrile was from Burdick & Jackson. All other reagents including 4,13-diaza-18crown-6 (1,4,10,13-tetraoxa-7,16 diazacyclooctadecane), formic acid, and ZrCl4 (purity >99.99
%) were obtained from the Aldrich Chemical Company.
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Representative HPLC-ESI mass spectra. As described in the accompanying
manuscript, a total of 500 µM of oxidized bovine insulin chain B was treated with 10 mM ZrCl4
in 20 mM 4,13-diaza-18-cown-6 from t = 4 h to t = 8 h at pH 7.0 and 60 °C. Peptide hydrolysis
products were then identified by HPLC-electrospray ionization mass spectrometry (HPLC-ESI
MS). Shown in Figures 2.4, 2.5, 2.6 are representative ESI mass spectra at HPLC elution times
of 18.36 min, 23.54 min, and 31.70 min, respectively.
Zirconium(IV)-assisted deamidation and lactamization reactions.
Zirconium(IV)-assisted deamidation.

HPLC-ESI analyses of the ZrIV hydrolysis

reactions detected the production of apparent trace quantities of the following three sets of
chromatographically separable insulin chain B peptide fragments: B†(1) and B†(2); D†(1) and
D†(2); and F†(1) and F†(2) (Table 2.1.). Fragments B†(1) at m/z 909.3, D†(1) at m/z 966.4, and
F†(1) at m/z 1053.5 were all observed to have masses that were approximately one mass unit
higher than the parent peptides B (Phe1 to Cys(SO3H)7, at m/z 908.3), D (Phe1 to Gly8, at m/z
965.5), F (Phe1 to Ser9, at m/z 1052.5; Table 2.1.). This result indicated that B†(1), D†(1), and
F†(1) could be deamidated forms of the starting material with either Asn3 or Gln4 being
converted to α-Asp3, α-Glu4, or to the geometric isomers β-Asp and γ-Glu.1 Fragment B†(2) at
m/z 910.3, D†(2) at m/z 967.4, and F†(2) at m/z 1054.4, were all approximately two mass units
higher that the parent peptides B, D, and F. Therefore, B†(2), D†(2), and F†(2) were proposed to
be doubly deamidated. We then employed ESI-MS/MS sequencing to demonstrate that the three
sets of fragments were indeed produced by deamidation of parent peptides B, D, and F: in B†(1),
D†(1), and F†(1), Gln4 in the corresponding parent was converted to Glu4; in B†(2), D†(2), and
F†(2), Asn3 and Gln4 were deamidated to Asp3 and Glu4.
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Figure 2.4. HPLC-ESI mass spectrum at an HPLC elution time of 18.36 min. Oxidized bovine
insulin chain B was treated with ZrIV/4,13-diaza-18-crown-6 for t=8 h. In the spectrum are the
singly and doubly charged observed masses corresponding to insulin chain B hydrolysis
fragment Phe1 to Cys(SO3H)7 (fragment B, Table 2.1.). The spectrum was acquired in positive
ion mode.

Figure 2.5. HPLC-ESI mass spectrum at an HPLC elution time of 23.54 min. Oxidized bovine
insulin chain B was treated with ZrIV/4,13-diaza-18-crown-6 for t = 4. In the spectrum are the
doubly and triply charged observed masses corresponding to insulin chain B hydrolysis
fragments Gly20 to Ala30 (fragment I, Table 2.1.) and Glu21 to Ala30 (fragment K, Table 2.1.).
The spectrum was acquired in positive ion mode.
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Figure 2.6. Representative HPLC-ESI mass spectrum at an HPLC elution time of 31.70 min.
Oxidized bovine insulin chain B was treated with ZrIV/4,13-diaza-18-crown-6 for t = 4 h. In the
spectrum are the doubly and triply charged observed masses corresponding to insulin B chain
hydrolysis fragments Gly8 to Ala30 (fragment C, Table 2.1.) and Ser9 to Ala30 (fragment E,
Table 2.1.). The spectrum was acquired in positive ion mode.
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Figures 2.4, 2.5, and 2.6 show representative ESI spectra with singly- and doublycharged spectra of the major products. Shown in Figure 2.7 are representative HPLC-ESIMS/MS spectra acquired from precursor ions at m/z 965.5 (Fragment D, HPLC elution time
18.50 min), at m/z 966.4 (Fragment D†(1), HPLC elution time 19.82 min), and at m/z 967.4
(Fragment D†(2), HPLC elution time 20.54 min). A side by side comparison of successive Nterminal fragment ions b3 to b5 and of successive C-terminal fragment ions y4 to y6 confirms the
deamidation patterns described above. Because peptide deamidation at neutral pH is associated
with the formation of α-Asp and β-Asp in a 1:3 ratio and α-Glu and γ-Glu in a 1:1.7 ratio,1a-b we
propose that insulin chain B fragments B†(1) and (2), D†(1) and (2), and F†(1) and (2) are likely
to consist of mixtures of geometric isomers. With respect to parent fragments B, D, and F, the
MS/MS data consistently revealed preferential deamidation of Gln4 over Asn3. This result was
initially unexpected, in light of the fact that the majority of literature reports have maintained that
asparaginyl residues are more susceptible to hydrolytic deamidation under neutral conditions.2
Notwithstanding, deamidation rates are influenced by primary, secondary, tertiary, and
quaternary protein structures.3 Consistent with our results, glutamine deamidation has been
shown to be accelerated by flanking carboxyl side histidine residues (i.e., His5 in oxidized
bovine insulin chain B).4
Zirconium(IV)-assisted lactamization. In order to further substantiate that ZrIV is
capable of promoting lactamization in the presence of 4,13-diaza-18-crown-6, a total of 2 mM of
glutamate was reacted in the presence of 20 mM of the azacrown ether, with and without 10 mM
of ZrCl4. After 24 h of treatment at pH 7.0 and 60 °C, significant conversion of Glu (m/z 146.4)
to pyroGlu (m/z 128.5) was observed in the reaction containing ZrIV/4,13-diaza-18-crown-6, and
not in the reaction in which ZrIV was substituted by an equivalent volume of water (Figure 2.8.).
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Figure 2.7. Comparison of MS/MS spectra for Fragment D: Phe1-Gly8 and deamidation
products. A total of 500 µM of oxidized bovine insulin chain B was treated with 10 mM ZrCl4 in
20 mM 4,13-diaza-18-crown-6 for t = 8 h at pH 7.0 and 60 °C. The MS/MS spectra show Nterminal b-ions and C-terminal y-ions generated from m/z 965.5 (Fragment D: Phe1-Gly8), from
m/z 966.4 (Fragment D‡(1): Gln4 in D converted to Glu4) and from m/z 967.4 (Fragment D‡(2):
Asn3 and Gln4 in D converted to Asp3 and Glu4). The m/z values in bold are rounded to the
nearest Da. The spectra were acquired in positive ion mode.
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Figure 2.8. ESI mass spectra of glutamate treated at pH 7.0 and 60 °C. (a) & (b): A total of 2
mM of Glu was reacted with 10 mM of ZrCl4 in the presence of 20 mM 4,13-diaza-18-crown-6
for 0 h and 24 h, respectively. (c) & (d): A total of 2 mM of Glu in 20 mM 4,13-diaza-18-crown6 was treated for 0 h and 24 h, respectively (no ZrCl4). “Glu” identifies glutamate; “pyroGlu”
identifies pyroglutamate. The spectra were acquired in negative ion mode.
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Table 2.1. HPLC-ESI-MS analysis of peptides observed after oxidized bovine insulin chain B
was reacted in the presence of ZrCl4 and 4,13-diaza-18-crown-6 (pH 7.0 and 60 °C)
Peak
assignment

A:
Phe1 to Ala30
B:
Phe1 to Cys(SO3H)7
B†(1):
Gln4→Glu4
B†(2):
Asn3→Asp3, Gln4→Glu4
C:
Gly8 to Ala30
D:
Phe1 to Gly8
D†(1):
Gln4→Glu4
D†(2):
Asn3→Asp3, Gln4→Glu4
E:
Ser9 to Ala30
F:
Phe1 to Ser9
F†(1):
Gln4→Glu4
F†(2):
Asn3→Asp3, Gln4→Glu4
G:
His10 to Ala30
H:
Phe1 to Cys(SO3H)19
I:
Gly20 to Ala30
J:
Phe1 to Gly20
K:
Glu21 to Ala30
K‡:
Glu21→pyro(Glu21)
L:
Phe1 to Leu6
M:
Leu6 to Tyr16
a

Elution
time
(min)

Relative
abundance
HPLC (%)

m/z singly charged
peptide

m/z doubly charged

m/z triply charged

t = 4h

t = 8h

obsd

calcd

obsd

calcd

obsd

calcd

33.82

100

100

no

3494.7

1747.8

1747.8

1165.5*

1165.6

18.36

11

50

908.3*

908.4

454.6

454.7

no

303.5

19.73

2

3

909.3*

909.4

455.1

455.2

no

303.8

20.46

2

3

910.3*

910.4

455.6

455.7

no

304.1

31.70

12

7

no

2605.3

1303.0

1303.1

869.1*

869.1

18.50

11

50

965.5*

965.4

483.2*

483.2

322.7

322.5

19.82

2

3

966.4*

966.4

483.6

483.7

no

322.5

20.54

2

3

967.4*

967.4

484.2

484.2

no

323.1

31.70

12

7

no

2548.3

1274.5

1274.6

850.0*

850.1

18.74

11

50

1052.5*

1052.5

526.7

526.7

351.7

351.5

19.99

2

3

1053.4*

1053.4

527.2

527.2

no

351.8

20.67

2

3

1054.4*

1054.4

527.7

527.7

no

352.1

31.70

12

7

no

2461.2

1231.0*

1231.1

821.0

821.1

33.79

5

5

no

2241.0

1121.0

1121.0

748.0

747.7

23.54

9

44

1272.5

1272.6

636.8*

636.8

424.8

424.9

33.79

5

5

2298.2

2298.1

1149.4

1149.5

766.7*

766.7

23.54

9

44

1215.5

1215.6

608.3*

608.3

405.8

405.9

26.48

3

16

1197.5*

1197.6

599.3*

599.3

400.1

399.9

17.00

6

15

756.4*

757.4

378.6

379.2

no

253.1

28.11

1

4

no

1252.6

627.9

626.8

418.5

418.2

(oxidized bovine insulin chain B)0 = 0.5 mM; [ZrCl4]0 = 10 mM; [4,13-diaza-18-crown-6]0 = 20 mM. Data were acquired over
multiple trials. Representative HPLC chromatograms are in Figure 2.4, 2.5, and 2.6. of the accompanying manuscript. Peak
assignments highlighted in blue correspond to apparent major peptide hydrolysis products. Peak assignments in red correspond
to apparent intermediate peptide hydrolysis products. Peak assignments in green correspond to apparent trace peptide hydrolysis
products. Not observed = no. “*” indicates that peak assignments were confirmed by ESI-MS/MS sequencing. “†” indicates
deamidation of peptide: Asn3 to Asp3 and/or Gln4 to Glu4. “‡” indicates lactamization of N-terminal Glu21 to pyroglutamate21
(pyroGlu21).
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Continued Table 2.1.: HPLC-ESI-MS analysis of peptides observed after oxidized bovine
insulin chain B was reacted in the presence of ZrCl4 and 4,13-diaza-18-crown-6 (pH 7.0 and 60
°C)
Peak
assignment

N:
Gly8 to Cys(SO3H)19
O:
Gly8 to Gly20
P:
Ser9 to Cys(SO3H)19
Q:
Ser9 to Gly20
R:
His10 to Cys(SO3H)19
S:
His10 to Gly20
T:
His10 to Lys29
U:
Val2 to Ala30
V:
Leu11 to Ala30
W:
Gly23 to Ala30
X:
Phe24 to Ala30
a

Elution
time (min)

Relative
abundance
HPLC (%)

m/z singly charged
peptide

m/z doubly charged

m/z triply charged

t = 4h

t = 8h

obsd

calcd

obsd

calcd

obsd

calcd

29.70

1

1

1351.8

1351.7

676.3*

676.3

no

451.2

29.82

3

4

1408.6

1408.7

704.8

704.8

470.2

470.2

30.39

1

no

1294.5

1294.6

647.7

647.8

432.5

432.2

28.11

1

1

1351.8

1351.7

676.3*

676.3

451.5

451.2

33.40

2

2

1207.7

1207.6

604.73

604.3

403.5

403.2

27.90

1

1

1264.5

1264.6

632.8

632.8

422.5

422.2

29.61

1

1

no

2390.2

1195.4

1195.6

797.4

797.4

33.51

1

1

no

3347.6

1674.3

1674.3

1116.4

1116.5

33.79

1

1

no

2324.2

1162.5*

1162.6

775.4

775.4

25.82

6

25

930.5*

930.5

465.6

465.7

no

310.8

24.19

3

13

873.3*

873.4

437.1

437.1

no

291.8

(oxidized bovine insulin chain B)0 = 0.5 mM; [ZrCl4]0 = 10 mM; [4,13-diaza-18-crown-6]0 = 20 mM. Data were acquired over
multiple trials. Representative HPLC chromatograms are in Figure 2.4, 2.5, and 2.6 of the accompanying manuscript. Peak
assignments highlighted in blue correspond to apparent major peptide hydrolysis products. Peak assignments in red correspond
to apparent intermediate peptide hydrolysis products. Peak assignments in green correspond to apparent trace peptide hydrolysis
products. Not observed = no. “*” indicates that peak assignments were confirmed by ESI-MS/MS sequencing. “†” indicates
deamidation of peptide: Asn3 to Asp3 and/or Gln4 to Glu4. “‡” indicates lactamization of N-terminal Glu21 to pyroglutamate21
(pyroGlu21).
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Table 2.2. MALDI-TOF MS analysis of peptides observed after oxidized bovine insulin chain B
was reacted for 4.2 h in the presence of ZrCl4 and 4,13-diaza-18-crown-6 (pH 7.2 and 60 °C)
Peak assignment

Relative
abundance MS
(%)
t = 4.2 h

m/z singly charged
peptide
obsd

calcd

m/z doubly charged
peptide
obsd

calcd

A:
22
3494.65
3494.65
1747.81
1747.83
Phe1 to Ala30
C:
18
2605.21
2605.28
no
1303.14
Gly8 to Ala30
E:
54
2548.16
2548.26
no
1274.63
Ser9 to Ala30
G:
21
2461.13
2461.22
no
1231.11
His10 to Ala30
I:
30
1272.63
1272.64
no
636.82
Gly20 to Ala30
K‡:
100
1197.60*
1197.61
no
599.31
(Glu21→pyroGlu21)
M:
1
1252.68
1252.59
no
626.80
Leu6 to Tyr16
T:
1
2390.12
2390.19
no
1195.60
His10 to Lys29
U:
3
3347.48
3347.58
no
1674.29
Val2 to Ala30
V:
1
2324.08
2324.16
no
1162.58
Leu11 to Ala30
a
[oxidized bovine insulin chain B]0 = 1 mM; [ZrCl4]0 = 10 mM; [4,13-diaza-18-crown-6]0 = 20
mM. Data were acquired over multiple trials. Representative MALDI-TOF mass spectra are
in Figure 2.3 of the accompanying manuscript. Peak assignments highlighted in blue
correspond to apparent major peptide hydrolysis products. Peak assignments in red correspond
to apparent intermediate peptide hydrolysis products. Peak assignments in green correspond to
apparent trace peptide hydrolysis products. Not observed = no. “*” indicates that peak
assignments were confirmed by ESI-MS/MS sequencing. “‡” indicates lactamization of Nterminal Glu21 to pyroglutamate21 (pyroGlu21).
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Epilogue.

Deamidation of a dipeptide by ZrIV metal.
Deamidation results in the formation of glutamate from glutamine residues or aspartate
from asparagine residues by hydrolysis. The deamidated products may also include geometric
isomers such as iso-Glu and iso-Asp.1a-b In addition to ZrIV, a number of metal ions, including
CeIII, CeIV, LaIII, and ThIV, are known to promote deamidation of glutamine to glutamate and of
asparagines to aspartate.2 As mentioned previously, side reaction of zirconium hydrolysis in our
data is deamidation of Asn3 and/or Gln4 residues in those hydrolysis products of insulin chain B
which contained the two residues including the products Phe1-Cys(SO3H)7 (m/z 906), Phe1Gly8 (m/z 965), and Phe1-Ser9 (m/z 1052). (Figure 2.1, Table 2.1) which all showed minor +1
and +2 Da analogs which were chromatographically separable by HPLC. The MS/MS spectra
also contained some Asn- and Gln-containing fragments which had a +1 and +2 Da shift.
In order to confirm that ZrIV promotes deamidation of glutamine in the presence of 4,13diaza-18-crown-6, a total of 2 mM of the dipeptide GlyGln was reacted in the presence of 20
mM azacrown ether, with and without 10 mM of ZrCl4 as shown in Figure 2.9. A similar
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experiment was performed with the single amino acid Gln (data now shown). After 36 h of
treatment at pH 7.0 and 60 °C, significant amounts of the hydrolyzed glutamine (m/z 147.1) was
converted to the deamidated glutamate (m/z 148.1) product as observed in the reaction containing
ZrIV / 4,13-diaza-18-crown-6 and not in the reaction where ZrIV was omitted. The absence of
deamidated glutamine from the single amino acid glutamine indicates that internal peptide
cleavage produces the deamidated product.

Glutamine presumably deamidates through a

glutarimide intermediate while asparagine deamidates through a succinimide intermediate.
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Figure 2.9. ESI mass spectra show deamidation of glutamine hydrolysis product to glutamate
only in the presence of ZrIV and azacrown ether (left). Spectra a) and b): 2 mM GlyGln was
reacted with 10 mM ZrIV and 20 mM azacrown ether for 0 h and 36 h, respectively (60 °C and
pH 6.90). Spectra c) and d): 2 mM GlyGln was reacted with 20 mM azacrown ether (no metal)
for 0 and 36 h, respectively (60 °C and pH 7.15). Spectra were acquired in positive ion mode.
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CHAPTER III METAL-ASSISTED HYDROLYSIS OF SPHINGOMYELIN.

Abstract.

Niemann-Pick diseases types A and B are incurable lysosomal storage disorders caused
by defective activity of the lysosomal enzyme acid sphingomyelinase, whose normal role is to
hydrolyze the phospholipid sphingomyelin. In the severe phenotype A, there is a lethal build-up
of sphingomyelin within the lysosomes of affected patients, with death by age 1 or 2 years.1 We
have demonstrated that ZrIV complexes can hydrolyze the phosphate ester bond in
sphingomyelin, and may possibly be developed as possible therapeutic tools in the treatment of
Niemann-Pick disease, since ZrIV complexes have the potential to mimic acid sphingomyelinase.
ZrIV hydrolysis of the phosphate ester bonds in sphingomyelin has been characterized by an
assay that quantifies phosphocholine, which is the same proteolytic product produced by the
active enzyme. Since the highest hydrolytic yields of DNA2 and acetylated peptides3 by ZrIV is
lysosomal pH 4.8 compared to cytosolic pH 7.0, we would like to develop phospholipid
hydrolysis protocols to confirm that ZrIV complexes hydrolyze sphingomyelin more efficiently at
pH 4.8 and 37 °C than pH 7. We have found that ZrIV in the presence of piperazine hydrolyzes
sphingomyelin in good yields at 60 °C and pH 4.8 within 20 h. Since the amphiphilic
sphingomyelin molecule exists physiologically in liposomes with bilayer structures, we have
conducted Triton X-100 liposome-micelle transition studies and characterization protocols based
on atomic force microscopy and UV-visible spectrophotometry to observe the effect of liposome
solubilization. The effects of micelle formation by addition of Triton X-100 surfactant have been
evaluated to increase the efficiency of metal-assisted phospholipid hydrolysis as a function of
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temperature and pH. Also, the effect of membrane-bound cholesterol on hydrolysis yields has
been investigated. We have demonstrated that zirconium hydrolyzes the phosphate ester bonds in
two colorimetric assays which measure either free phosphate or phosphocholine/choline
concentrations. Metals used by other researchers to hydrolyze unactivated amide and phosphate
ester bonds 4-16 have been used to hydrolyze sphingomyelin for comparison to ZrIV. These metals
include CuII, CoII, CeIV, EuIII, NiII, PdII, LaIII, YIII, YbIII, and ZnII. For each metal, we have
examined the increase in hydrolysis at lysosomal pH 4.8 compared to the cytosolic pH 7.0.
Introduction.
Metal-assisted hydrolysis of phospholipids.
Metals have been demonstrated to be effective reagents in the hydrolysis of the phosphate
ester bond of substrates such as nucleic acids, synthetic phospholipids, and phosphorylated
sugars. Metals, particularly lanthanide, actinides, rare earth, and tetravalent transition metals are
excellent hydrolytic reagents because of their dual ability to neutralize the phosphate anionic
charge and to provide a nucleophile using their deprotonated bound waters of hydration.4-16
Figure 3.1 ranks the metals used in this study with their respective hydrolysis constants (pKa) of
the water-bound metal species. The tetravalent metal ions CeIV, ZrIV, HfIV, and divalent PdII
lower the pKa of water from 15.7 to < 2 and, thereby, form metal-hydroxide species when
dissolved in aqueous hydrolysis reactions at pH 4.8 or 7.17-20 The metal ion zirconium(IV) has
been found to efficiently hydrolyze amide bonds in peptides.21 ZrIV also hydrolyzes phosphate
ester bonds in a synthetic p-nitrophenol activated phosphate ester.7,9,10,11,13,15 According to these
studies, cleavage levels were substantially increased when the reaction pH was changed from 7.0
to more acidic pH values in the range of 4.0-4.7, which is near the lysosomal pH of 4.8.
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The metal-assisted hydrolysis of the phosphate ester bond of biological phospholipids
involved in cell membrane structures is a novel approach to the development of therapeutic drugs
for use in the incurable lysosomal storage disease of Niemann-Pick disease A and B. These
disorders produce a lethal build-up of sphingomyelin in liver, spleen, and brain cells due to the
defective lysosomal acid sphingomyelinase enzyme. Selected metals were used in the present
study to represent a range of cellular toxicities, and selectivity toward the phosphate ester bond
in synthetic phospholipids and human phospholipids.7,11 The pH of the lysosomal interior is pH
4.8, and is thus considerably more acidic than the cytoplasm (pH 7.2). It is worthwhile to
investigate the pH-dependent reactivities of metals to estimate the increase in metal-assisted
hydrolytic cleavage of sphingomyelin in the lysosomes compared to cytosol. ZrIV is of particular
interest due to its low cellular toxicity and lack of natural metalloenzyme activity interference in
humans.22a-o The optimal hydrolysis of DNA and acetylated peptides by ZrIV has been shown to
be higher at (lysosomal) pH 4.8 than (cytosolic) pH 7.0.2-3 Table 3.1 shows various pH values
which are relevant to optimal ZrIV activity and lysosomal pH. The lysosomal pH is not only the
optimal pH of the acid sphingomyelinase enzyme which is defective in Niemann-Pick patients,
but is also approaching the optimal pH of ZrCl4 activity in the hydrolysis of acetylated Gly-Gly.2
There is strong motivation to use ZrIV and similar metals as therapeutic agents to target diseaserelated, lysosomal phospholipids such as sphingomyelin.
Sphingomyelin.
Sphingomyelin is a major phospholipid in animal plasma membranes and predominates
in the human brain, the myelin sheath of nerve cell axons, and in erythrocytes. It consists of a
phosphate group, sphingosine, choline, and an N-acyl linked fatty acid. The fatty acid content of
sphingosine and the N-acyl linked fatty acid varies, but palmitic (16:0), stearic (18:0) and
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nervonic acids (24:1) are the most abundant in humans. Approximately 60 % of the fatty acids of
of the sphingomyelin of the grey matter of the human brain consist of stearic acid (18:0) while
60 % of the corresponding sphingomyelin in the white brain matter consist of lignoceric (24:0)
and nervonic (24:1) acids.

Human sphingomyelin interdisperses with phosphatidylcholine and

cholesterol in the exoplasmic layer of the plasma membrane lipid bilayer. The fatty acids which
predominate

in

sphingomyelin

of

plasma

membranes

are

more

saturated

than

phosphatidylcholine. The sphingosine-bound fatty acid is typically longer than the N-acyl linked
fatty acid moiety which introduces length assymetry.23-24 Figure 3.2 shows the structure of
sphingomyelin along with two possible hydrolysis products of phosphocholine and choline.
Figure 3.3 shows the structures of piperazine and HEPES which are the buffers used in the
hydrolysis reactions described in this dissertation since their pKa values corresponded to
lysosomal pH 4.8 or to cytosolic pH 7, respectively. Figure 3.4 shows the polar and nonpolar
regions of sphingomyelin along with the two possible metal-assisted hydrolytic pathways which
produce either phosphocholine or choline. Sphingomyelin is capable of both intra- and intermolecular bonding. The amide group’s nitrogen and the hydroxyl on the sphingosine moiety are
hydrogen donor sites, while the amide carbonyl oxygen provides a hydrogen acceptor site.
Intramolecular bonding occurs between the free hydroxyl on the sphingosine base and the
phosphate ester oxygen. Intermolecular bonding arises from van der Waals forces between the
hydrocarbon chains and cholesterol which associates with sphingomyelin in membranes. The
intermolecular bonding is decreased in the case of the trans double bond in the nervonic acid
fatty acid. The configuration of human sphingomyelin is the enantiomerically pure form of Derythro with two chiral centers formed by the sphingosine free hydroxyl (C3) and the amide NH2
(C2) groups in the 2S, 3R configuration.
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Figure 3.1. Deprotonation of the waters of hydration on selected metal ions. Encircled metals
demonstrate the highest hydrolysis yields in metal-assisted hydrolysis of phospholipids as
discussed in this chapter.The pKa data were taken from Metal Ions in Solution, 1978, p. 356 by
John Burgess.17
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Table 3.1. The correlation of biological pH values to optimal pH of ZrIV-assisted hydrolysis.
Cellular location or experiment

Optimal pH

Lysosome

pH 4.8

Cytosol

pH 7.2

Optimal activity of acid sphingomyelinase

pH 4.8
(inactive at pH 7.0)

Maximum reactivity of 20 mM ZrCl4 hydrolysis of DNA at 20 °C 2

pH 4.0

Optimal activity of ZrIV-assisted hydrolysis of AcGG at 37 °C, 45 °C,
and 60 °C 3

pH 4.4
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(a)

(b)

(c)

Figure 3.2. (a) Structure of sphingomyelin; (b) structure of phosphocholine; (c) structure of
choline.

H2
N

(a)

N
H

(b)

Figure 3.3. The molecular structures of the buffers used in our hydrolysis experiments: (a)
piperazine (lysosomal pH 4.8); (b) HEPES (cytosolic pH 7). The piperazine and HEPES
structures show the protonation site responsible for the pKa values.40
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Polar Headgroup = Choline + PO4 -

Hydrophobic Tails = Sphingosine + N-acyl Linked Fatty Acid = Ceramide

Hydrolysis pathway of acid
sphingomyelinase

Alternate hydrolysis
pathway

Figure 3.4. Diagram of the metal-assisted phosphate ester bond hydrolysis of sphingomyelin to
either phosphocholine or choline products. The sphingomyelin structure contains a polar
headgroup and a non-polar hydrophobic tail.
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The acyl chain composition of sphingomyelin determines the gel to liquid-crystalline phase
transition temperature and the enthalpy of transition. The gel to liquid-crystalline phase transition
for pure sphingomyelin is the physiological temperature of 37 °C. The transition temperature is
governed by phosphocholine head group repulsion and hydrocarbon chain packing. 23-31
Cholesterol is closely associated with sphingomyelin in amounts up to 45 mol % in
normal cell membranes, but accumulates to a much higher percentage in Niemann-Pick diseased
cells. It controls membrane fluidity by restricting acyl chain motion and reduces permeability of
the membrane. The cholesterol molecule consists of a polar hydroxyl group which hydrogen
bonds with the polar head of sphingomyelin and a nonpolar sterol center and a hydrocarbon
chain of 7 carbons which are embedded in the nonpolar fatty acid tails of the inner
sphingomyelin bilayer.23-24 The addition of 30 mol % of cholesterol to sphingomyelin eliminates
the gel-to-liquid crystalline phase transition.28 Cholesterol also increases the detergent resistance
of sphingomyelin in plasma membranes.27
In normal cells, sphingomyelin exists physiologically as liposomes. However, the
speciation of sphingomyelin in Niemann-Pick disease is unknown. Therefore, the incorporation
of Triton X-100 to solubilize the normal vesicle structures was undertaken. Triton X-100 is a
nonionic surfactant commonly used to solubilize phospholipid vesicles in many studies in order
to induce a transition from vesicles to micelles with intermediate mixed populations.32a-k Figure
3.5 shows the transition envisioned by Lopez et al.32f with five stages: pure vesicles, enlarged
vesicles with interdispersed Triton X-100, saturated bilayered vesicles plus detached micelles for
a mixed population, a predominate micellar population with few saturated bilayers, and, finally,
a population consisting of exclusively micelles with sphingomyelin interdispersed with Triton X100.
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= 9.5

Increasing Triton X-100 amounts

Figure 3.5. Schematic of Triton X-100 induced phospholipid vesicle to micelle transition, Lopez
et al, FEBS Letters, 1998,32f shown along with the structure of Triton X-100. The ethylene oxide
units have n = 9.5 according to manufacturer label.
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In the in vivo enzymatic reaction of acid sphingomylinase, the hydrolysis of
sphingomyelin occurs at the phosphate ester bond between the phosphocholine and sphingosine
to release phosphocholine and a ceramide as shown in Figure 3.4. In order for metal-assisted
hydrolysis to mimic the enzyme, the metal will be oxophilic and a hard Lewis acid in order
toactivate the phosphate ester bond. Ideally as an enzyme mimic, the hydrolysis reaction should
be regioselective and cleave only one side of the phosphate ester. Tetravalent metals such as
ZrIV, CeIV, and HfIV are oxophilic with high charge density and, as we show, are capable of
hydrolyzing the phosphate ester bond of sphingomyelin to yield a phosphocholine and a
ceramide. If the metals lack regioselectivity, the hydrolysis will produce a choline and
phosphoceramide.
Niemann-Pick disease.
Niemann-Pick disease (NPD)33a-i is an incurable, autosomal recessive, lysosomal storage
disorder with two phenotypes A and B. Type A primarily affects Ashkenazic Jews with infant
mortality while type B affects other diverse ethnic groups with middle age mortality. The NPD
forms A and B result from over 18 mutations on the acid sphingomyelinase gene in chromosome
11, and both types A and B are associated with very low acid sphingomyelinase activity
compared to the wild type. Approximately 80 % of NPD patients are Type A. The majority of
the Type A patients of European Jewish ancestry have a 1:90 type A gene carrier rate and
1:30,000 physical disease occurrence. The defective enzyme acid sphingomyelinase has only 13% normal activity in type A while type B has 10-60 % of normal enzyme activity, and both
result in fatal accumulation of sphingomyelin in the lysosomes. Based on the autopsies of
Niemann-Pick patients in several studies, sphingomyelin accumulated in the spleen is 15 - 99
µmol of sphingomyelin per g of wet tissue compared to the control spleens at 2 - 4 µmol per g of
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wet tissue.33a-b The affected organs in type A are the spleen, lymph nodes’ monocytemacrophage system, liver, kidneys, brain, and lung, while type B has similar patterns except for a
lack of accumulation in the brain. Cholesterol also builds up in the lysosomes, most probably
due to the interdispersion of cholesterol with sphingomyelin in the periplasmic membrane.
Enzyme replacement and chemical chaperones have had limited therapeutic success in treating
Niemann-Pick patients.33a-i

A novel therapeutic cure based on ZrIV-assisted phospholipid

hydrolysis is the concept developed in this dissertation. This approach would serve to decrease
this fatal accumulation of sphingomyelin in NPD patients. Since ZrIV is redox-inactive and
possesses low cellular toxicity, a ZrIV complex which efficiently hydrolyzes sphingomyelin at the
same hydrolytic bonds and pH values as the acid sphingomyelinase enzyme may function as an
enzymatic mimic.
Methods.
Purchases.
All metals were purchased from Sigma-Aldrich and all had a purity of 99.999% except
for potassium tetrachloropalladate(II) (K2PdCl4) and europium(III) chloride hexahydrate (EuCl36H2O) (99.99%), hafnium(IV) tetrachloride (HfCl4) (98%), and bis(cyclopentidienyl)
zirconocene(IV) dichloride (C10H10Cl2Zr) (>98%). Metal hydrolytic activity was assayed on
vesicles composed of pure sphingomyelin without and with cholesterol. Porcine brain
sphingomyelin was purchased from Avanti Polar Lipids (860062P) and was used without further
purification. The sphingomyelin has a reported gel-liquid transition temperature at ca. 35 °C and
is a heterogeneous mixture of 18:0 stearic acid (49%), 24:1 nervonic acid (20%), and 31%
various (16:0, 20:0, 22:0, 24:0, and other) fatty acid composition.34 Observed MALDI mass
peaks of the sodium adducts at m/z 753 and m/z 835 correlate to the stearic and nervonic fatty
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acid content. Triton X-100 solution (93443) was purchased from Fluka BioChemika. HEPES
sodium salt (H7006) was purchased from Sigma-Aldrich, and piperazine anhydrous buffer
(80621) was purchased from Fluka. Cholesterol (C8667) was purchased from Sigma in 99%
purity.
Metal-assisted hydrolysis.
The sphingomyelin liposomes were prepared by sonication as follows.

The

sphingomyelin was dissolved in chloroform. This solution was evaporated overnight to produce
a dry film followed by 2 h of drying under vacuum. For cholesterol experiments, the dried
sphingomyelin and cholesterol were dissolved together in chloroform and the solution
evaporated by the same protocol. The dried sphingomyelin was hydrated to a concentration of
100 mM in pre-heated doubly-deionized H2O at 55 °C, a temperature that is above the gel-liquid
crystal transition temperature of sphingomyelin. The aqueous suspension was placed in a water
bath and sonicated for 30 min (45 min for cholesterol experiments) to produce a milky
suspension with a high surface tension. These liposomes are assumed by definition to be small,
unilamellar vesicles (SUVs) and were later examined by atomic force microscopy (AFM).
Hydrolysis reactions of liposomes prepared from the stock sphingomyelin solution in
1000 µl volumes contained a final concentration of 2 mM sphingomyelin, 10 mM metal and 20
mM piperazine (pH 4.8) or HEPES (pH 7) buffer. The metals included period 4, 5, and 6 metals
Ce(NH4)2(NO3)6, ZrCl4, HfCl4, K2PdCl4, CuCl2-2H2O, ZnCl2, CoCl2-H2O, NiCl2-6H2O, EuCl36H2O, LaCl3-H2O, YCl3-6H2O, and YbCl3-6H2O. The metal and the buffer were premixed and
pH-adjusted to 4.8 or 7.0 with HCl or NaOH prior to adding to the final volume of the diluted
aqueous sphingomyelin stock solution. For solutions containing surfactant, the Triton X-100 was
vortexed with the aqueous sonicated sphingomyelin solution at 25 °C and pre-equilibrated for at
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least 30 minutes prior to the dilution and metal/buffer addition. The final Triton X-100
concentrations were either 0, 2, or 16 mM. Individual reactions were placed on an Eppendorf
Thermomixer R preheated to 60 °C or 37 °C for 20 h at 500 rpm.
Malachite green assay and turbidity.
A Quantichrom Phosphate Assay™ (Bioassay Systems, Inc.) was used to detect free
inorganic phosphate. A Shimadzu UV-1601 UV-visible spectrophotometer was used to record
the absorbance at 620 nm with total acquisition in the 1100-300 nm range.39 The inorganic
phosphate is released as a secondary cleavage product after sequential hydrolysis of both
sphingomyelin phosphate ester bonds. This assay utilizes the complexation of molybdate and
phosphate ions to form a heteropolyphosphomolybdate complex which is subsequently bound by
the dye malachite green.39 The malachite green assay utilized 25 µL for ZrIV (3 µL for CeIV
samples) samples, 142 µL for ZrIV (164 µL for CeIV) H2O, and 333 µL malachite green assay
reagent for a total volume of 500 µL. The solutions were vortexed after each addition, and
spectrally analyzed after 30 min. Positive controls of phosphocholine and choline that were
prepared and reacted with similar metal/buffer concentrations at 60 ±C for 20 h were used to
determine statistical accuracy of the assay.
In order to correct for background levels of inorganic phosphate, the absorbance
differences at both 0 h and 20 h for all of the metal reactions and for parallel control reaction
ions run in the absence of metal were measured. Histograms were developed by subtracting the
absorbance difference (20 h – 0 h) in the absence of metal from the absorbance difference (20 h –
0 h) in the presence of metal to yield a background-subtracted absorbance difference that
represents phosphate released only from the metal-assisted reaction.

66

Standard curves.
A series of solutions of increasing phosphate concentration and a constant 10 mM metal
and 20 mM buffer concentrations as the assayed hydrolysis samples were prepared in the
absence of Triton X-100 in order to quantify the malachite green assay results and assess
experimental metal interference with the molybdenum-phosphate-malachite green assay. Parallel
non-metal control phosphate standards containing only 20 mM buffer were also measured.
Solutions of 100 mM metal and 200 mM piperazine or HEPES buffer were prepared and mixed
1:1 v/v. The premixed 1:1 metal/buffer solution was pH-adjusted to either 4.8 or 7.0 with either
HCl or NaOH and heated at 60 °C for 20 h. The dilution of 25 µL of a typical hydrolysis reaction
sample to 500 µL total volume in a malachite green assay represents a 20-fold dilution of the
sample so the diluted standards were prepared with similar metal/buffer concentrations as the
diluted hydrolysis sample. The 30 µM phosphate stock solution was included in the Quantichrom
Phosphate Assay™ kit from which a total of 9 different phosphate concentrations were prepared
in the range of 0-11 µM at a total volume of 500 µL each. The amount of 30 µM phosphate stock
solution, premixed 1:1 metal/buffer solution to give a final solution of 0.5 mM metal/1 mM
buffer concentration, doubly-deionized water were mixed first followed by addition of 333 µl
malachite green reagent. The total volume was mixed thoroughly and allowed to equilibrate for
30 minutes. In summary, the final concentrations of the standard solutions for all metals except
cerium(IV) were 0, 1, 3, 5, 7, 8, 9, 10, 11 µM of inorganic phosphate in 0.5 mM metal, and 1
mM buffer in a total volume of 500 µL with two exceptions in the highest standards of 10 and 11
µM which each had 507 µL and 538 µL volumes. The two highest phosphate standards had a
higher total volume (> 500 µL) in order to maintain the same malachite green reagent amount in
all standard solutions. An example of a 5 µM phosphate standard would be prepared from 84 µL
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of the 30 µM phosphate stock solution, 5 µL of the 1:1 metal/buffer solution, 78 µL doublydeionized water, and 333 µL malachite green reagent for a total volume of 500 µL. The cerium
standards were prepared with similar procedures except the 1:1 metal/buffer solutions were
diluted 10-fold, i.e. 5 mM cerium(IV) metal ion concentration and 10 mM buffer concentration
at this step, in water prior to addition to each standard because of the greater dilution of cerium
reaction samples, e.g. 3 µL reaction sample instead of 25 µL diluted to 500 µL which is a 166.7fold dilution. The final metal and buffer concentrations in the cerium(IV) samples were 60 µM
cerium(IV) metal ion and 120 µM buffer. The standards prepared for the non-metal control
samples were prepared with the 30 µL stock phosphate solution, 200 mM buffer (final buffer
concentration in standard is 1 mM), doubly-deionized water, and malachite green reagent for a
total volume of 500 µL. The standards were analyzed on a Shimadzu UV-1601 instrument in the
1100-300 nm range. The slope equations were determined from phosphate concentration plotted
against absorbance at 620 nm and yielded linear slopes with correlation coefficients of r = 0.999.
Turbidity measurements were conducted on the liposomes to gain additional insight into
the vesicle to micelle transition. Solubilization with Triton X-100 was measured as a decrease in
turbidity of the sphingomyelin vesicle suspensions at 500 nm absorbance. Turbidity was
measured on 2 mM sphingomyelin in piperazine buffer at pH 4.8 without metal with increasing
amounts of Triton X-100 (0-100 mM) on a Shimadzu UV-1601 spectrophotometer with
acquisition in the range of 1100-300 nm. Data absorbance at 500 nm was plotted.
Phosphocholine and choline quantification.
Phosphocholine and choline hydrolysis products were quantified with an Amplex Red
Sphingomyelinase Assay kit (Invitrogen-Molecular Probes) which uses a multi-enzyme
reaction series to produce H2O2 that reacts with the sensitive colorimetric Amplex Red
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reagent.35 All enzymes were prepared according to the kit’s instructions and the two-step
sphingomyelinase assay described in the kit was used since the lysosomal pH samples were in
the acidic pH range. Figure 3.6 illustrates the conversion of the phosphocholine and/or choline
substrates to a detectable product. The alkaline phosphatase enzyme converts phosphocholine to
choline which is subsequently converted by choline oxidase to betaine and H2O2. The H2O2
substrate in the presence of horseradish peroxidase reacts with Amplex Red reagent to produce
a red solution which was analyzed with a Shimadzu UV-1601 UV-visible spectrophotometer in
the acquisition range 300-1100 nm with the absorbance at 570 nm recorded for quantification
calculations. Since both phosphocholine and choline were possible hydrolytic products, the
results yielded the total phosphocholine and choline products from the hydrolysis reactions. In
order to distinguish the phosphocholine yields from the choline yields in the mixture, a novel
adaptation of the assay was developed by preparation of a parallel, multi-enzymatic reaction
series where the alkaline phosphatase enzyme was omitted to prevent any phosphocholine
hydrolysis product from being enzymatically converted to choline.
Dual sets of phosphocholine or choline standards were prepared for quantification of the
enzyme mixes with and without the alkaline phosphatase, respectively. The stock solutions of
phosphocholine and choline from which the standards were directly prepared were 100 mM
concentration serially diluted in 100 mM Tris buffer, pH 8, to a substock concentration of 1 mM
phosphocholine or choline in 100 mM Tris buffer with no metal or hydrolysis reaction buffer.
Many reaction samples were diluted 10-fold for the Amplex Red assay so the phosphocholine
and choline standards were prepared with 1 mM metal and 2 mM buffer final concentrations.
The metal and piperazine or HEPES stock solution was prepared with a concentration of 100
mM and 200 mM, respectively, and premixed in a 1:1 v/v solution with pH adjustment to pH 4.8
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or 7 depending on the experiment. The 1:1 premixed metal/buffer solutions were heated at 60 °C
for 20 h. Amounts of the 1 mM phosphocholine or choline substock solution, 20 µL of the 1:1
metal/buffer mix, and 100 mM Tris buffer, pH 8, were mixed for final phosphocholine or choline
concentrations of 0.005, 0.01, 0.02, 0.05, 0.08, 0.1, and 0.2 mM with a final metal/buffer
concentration of 1 mM metal and 2 mM buffer in a total volume of 1000 µL for each standard.
Each set included seven standards in the concentration range of 0 - 0.2 mM substrate and
produced slope equations with correlation coefficients of ≥ 0.99 in the 0 - 0.1 mM linear range of
the slope. Amounts of these phosphocholine and choline standard sets were later mixed with the
enzyme mix which is described below.
The enzyme mix stock solution components were prepared according to the kit’s
protocols. The final enzyme mix for the total phosphocholine plus choline quantification
included 100 µL horseradish peroxidase solution, 100 µL choline oxidase solution, 200 µL
alkaline phosphatase solution, 100 µL Amplex Red reagent solution, and 9.5 mL of 100 mM
Tris-HCl, pH 8.0. For the final enzyme mix for the choline-only assay, the amount of alkaline
phosphatase was substituted with an equivalent volume of 100 mM Tris-HCl, pH 8. The enzyme
mixes were used immediately without storage of the remaining, unused enzyme mix.
For the final assay sample preparations prior to the 37 °C incubation step, the following
protocol was performed. The hydrolysis reaction samples were diluted between 10 to 50-fold
with 100 mM Tris buffer, pH 8, in order to have absorbances in the linear standard range. For the
final, enzymatic sample preparation using the Amplex Red enzyme mixture, 50 µL of diluted
reaction sample or standard solution was mixed with 100 µL of either of the two enzyme mixes
described above containing horseradish peroxidase, choline oxidase, and alkaline phosphatase,
and the Amplex Red reagent. A second set of samples were prepared with the non-alkaline
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phosphatase enzyme mix for the choline-only quantification. Enzyme controls were prepared
with an equivalent amount of doubly-deionized water plus enzyme mix. The solutions were
gently stirred and placed in a 37 °C incubator for one hour. After one hour, the vials were placed
in the freezer to quench the enzymatic reactions. Immediately prior to analysis, 400 µL of
doubly-deionized water was added to each 150 µL sample, vortexed, and placed in a cuvette for
spectral acquisition. All data was acquired within hours of the sample preparation. All assays
were performed on the same day as the completion of the 20 h hydrolysis reactions.
Positive controls of phosphocholine and choline were prepared in a similar procedure as
the metal-assisted sphingomyelin reaction samples. Stock solutions of 55.82 mM phosphocholine
or 75.08 mM choline were prepared along with 100 mM metal and 200 mM piperazine or
HEPES buffer solutions. The metal and buffer were premixed in a 1:1 v/v solution, and the pH
was adjusted to pH 4.8 or 7 with HCl or NaOH. All positive control samples were prepared with
no Triton X-100 addition. The final concentrations of the metal-assisted phosphocholine or
choline reaction samples were 1.12 mM and 1.49 mM, respectively, in 10 mM metal and 20 mM
buffer concentrations. Positive controls of phosphocholine and choline were heated at 60 ±C for
20 h similar to the hydrolyzed sphingomyelin reactions. The hydrolyzed samples were diluted
50-fold in 100 mM Tris buffer, pH 8 prior to the Amplex Red assay to a final concentration of
22.4 µM original phosphocholine or 29.8 µM original choline in 100 mM Tris buffer, pH 8 with
diluted metal and buffer concentrations of 200 µM metal and 400 µM buffer. A total of 50 µL of
each of the diluted positive control reaction samples was added to 100 µL of either of the two
enzyme mixes containing the Amplex Red reagent and treated as described in the previous
paragraph.
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For the phosphate determinations, the positive control samples of phosphocholine and
choline were prepared according to the metal used in the hydrolysis reaction. If the sample was
hydrolyzed with zirconium(IV) metal, then 25 µL volumes of the 1.12 mM phosphocholine or
1.49 mM choline metal-assisted samples were added to 142 µL of doubly-deionized water and
vortexed. If the sample was hydrolyzed with cerium(IV) metal, then 3 µL of the 1.12 mM
phosphocholine or 1.49 mM choline metal-assisted samples were added to 164 µL doublydeionized water and vortexed. Next, 333 µL of the malachite green reagent was added to the
diluted sample mix (all metals) and vortexed. The green colorimetric solution developed for 30
minutes. Afterwards, the entire 500 µL volume was pipetted into a cuvette and spectrally
analyzed over the wavelength range of 300-1100 nm and the absorbances at 620 nm were
recorded.
Hydrogen peroxide positive controls were provided in the kit with the specific
concentration on the label which was ~ 3 %. Only new, unopened vials were used for the
controls since the hydrogen peroxide degrades quickly. Based on the precise concentration
indicated on the vial, e.g., precisely 3.3%, a 20 mM working solution of H2O2 was prepared by
dilution in doubly-deionized water. A second serial 10-fold dilution of this 20 mM H2O2 was
prepared by dilution with doubly-deionized water for a final substock solution of 0.22 mM H2O2.
From this substock solution, three different concentrations of 0.02, 0.04, and 0.06 mM were
prepared and analyzed by either the total phosphocholine plus choline or the modified cholineonly protocols described above with 50 µL hydrogen peroxide samples and 100 µL enzyme mix
with 1 h incubation at 37 °C.
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Atomic force microscopy.
Atomic force microscopy (AFM) was used to study the liposome preparations with
various amounts of Triton X-100 to determine the size and shape of the pure and solubilized
vesicles. Sphingomyelin vesicle suspensions equilibrated with 0, 2, or 16 mM Triton X-100
were imaged by AFM as follows. Aliquots of 10 µL were dried on mica substrates overnight and
imaged by a Veeco Multi Mode V instrumentation at a rate of 2.5 µM/s. Imaged data was
reviewed with Thermomicroscope SPMLab NT Ver. 5.01 software. The data included the image,
histograms, and cross-sectional views from selected areas of the image. The histograms recorded
the number of Z-heights from the probe to the nm-µm height range.
Results and discussion.
Liposome solubilization and turbidity.
Solubilization of liposomes by a detergent such as Triton X-100 provides a good model
for the solubilization of cell membranes. Triton X-100 is a nonionic detergent that has been used
to study the ability of surfactants to alter phospholipid bilayer structures with subsequent
conversion from vesicle to mixed micelle or pure micelle populations. Triton X-100 causes a
surfactant-dependent increase in phospholipid vesicle size as confirmed directly by light
scattering and indirectly by an increase in turbidity of sphingomyelin preparations.32f A gradual
increase in size with increasing Triton X-100 concentration and incorporation or interdigitation
as noted by electron micrographs was observed parallel to the increase in turbidity in several
studies.32a,c In these studies, turbidity was measured by recording the absorbance at 500 nm. The
turbidity curve in Figure 3.7 shows the millimolar concentrations of Triton X-100 and the
sphingomyelin lipid : Triton X-100 molar ratio as plotted against the absorbance at 500 nm. The
liposomal sizes affect the transmittance of the beam as reflected an increase or reduction in
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Figure 3.6. Molecular Probes Amplex Red sphingomyelinase assay: detection of choline
and phosphocholine products released upon metal-assisted hydrolysis of sphingomyelin.35
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absorbance at 500 nm. The graphs show an increase in turbidity in the Triton X-100 range of 1-3
mM (less than 1: 2 phospholipid: Triton X-100 ratio) with a sharp decline in the turbidity with
higher (> 3 mM) Triton X-100 concentrations. The sample appearance correspondingly changed
from cloudy to transparent over this concentration range.
These trends are postulated to correspond to the incorporation of Triton X-100 into the
vesicle structures with a resulting increase in size, and thus turbidity (1-3 mM Triton X-100
range of the curve) while the regionof negligible absorbance levels correspond to micelle
formation (≥ 5 mM Triton X-100).According to Figure 3.5, the incorporation of Triton X-100
involves several stages of vesicle incorporation of Triton X-100 with accompanying increase in
size and turbidity until saturation followed by subsequent transformation into breakaway
micelles with decreased size and turbidity. The Triton X-100 concentrations of 0, 2, and 16 mM
used in the hydrolysis represent distinctly different liposomal populations with pure vesicles (0
mM), mixed vesicle/micelle (2 mM), and pure micelles (16 mM). When cholesterol is added in
50 mol % of sphingomyelin, the turbidity pattern in Figure 3.8 shows an initial increase in
turbidity which increases slightly over the entire Triton X-100 concentration range of 5-100 mM.
Cholesterol increases resistance of sphingomyelin to solubilization as evidenced by the increased
turbidity even at very high Triton X-100 amounts.32j Tighter packing of sphingomyelin’s fatty
acid chains, which is induced by cholesterol, has been attributed to this resistance to detergent
solubility.27 Additionally, cholesterol is hydrophobic and will aggregate in solution. The
persistent increase in turbidity of the sphingomyelin liposomes prepared with 50 mol %
cholesterol over the entire Triton X-100 concentration range is consistent with the observed
solution cloudy appearance compared to solutions without cholesterol which become clear
(decrease in turbidity) with Triton X-100 concentrations ≥ 5 mM.
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Table 3.2. shows a summary of vesicle categories from various literature sources
where vesicle size ranges are provided for each category.

23,24,34

The small unilamellar vesicles

category (SUV) has a range of 15-30 nm and is typical of sonicated vesicle preparations; the
rarely-used intermediate unilamellar vesicle category ranges from 100-200 nm; the large
unilamellar vesicle category (LUV) ranges from 60-500 nm and is used frequently to describe
extruded liposome preparations. These ranges will be used to compare with the Z-heights
(approximation of the actual vesicle diameters) obtained by AFM images of the sphingomyelin
preparation vesicles.
Atomic force microscopy imagery.
AFM measures surface topography of soft solids including phospholipid vesicle bilayers
at nanomolar resolution. In this technique, the piezoelectric force between the probe tip and the
surface is quantitated and processed to display an image.36a-d Figure 3.9 shows a representative
image of a pure sphingomyelin vesicle preparation (0 mM Triton X-100). In Figure 3.9 (a), the
1D image shows distinct, round particles which can correspond to small, unilamellar vesicles
with a mean Z-height of 40 ≤ 12 nm. From this Z-height, the diameter of 40 nm is classified as
SUV. The histogram for this image shows a medium distribution. For comparison, Figure 3.9 (b)
shows pure phosphatidylcholine vesicles prepared by aqueous sonication from a dried lipid film
prepared by Leonenko et al.36b to demonstrate the similarity in vesicle shape for two
phospholipids. The average diameter in that study was 22 ≤ 2 nm. Vesicles prepared by bath
sonication typically produce SUVs.34
The vesicles prepared with 2 mM and 16 mM Triton X-100 revealed anomalous images
(data not shown). The 2 mM Triton X-100 solubilized vesicles featured two distinct image types
which may explain the larger standard deviations in the hydrolysis yield data associated with this
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Figure 3.7. Graph shows the turbidity measurements of the vesicle to micelle transition of 2 mM
sphingomyelin in 20 mM piperazine buffer with 0 - 25 mM Triton X-100. The x-axis is the
concentration of Triton X-100 and the lower axis shows the molar ratio of lipid: Triton X-100.
The y-axis is the absorbance at 500 nm. The inset shows similar results with egg yolk lecithindicetylphosphate vesicles taken from Alonso, Villena, Goñi, FEBS Lett., 1981.32c The number of
trials = 4.
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Figure 3.8. Comparison of turbidity for sphingomyelin without and with (0, 50 mole %)
cholesterol. Graph shows a comparison of the data shown in Figure 3.7 with the turbidity
measurements of 2 mM sphingomyelin in 20 mM piperazine buffer and 1 mM cholesterol with 0
- 100 mM Triton X-100 addition.
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Table 3.2. Summary of vesicle size categories from literature sources.*

Liposome Category

Diameter size
range 24

Diameter size
range 23

Diameter size
range 34

Small unilamellar vesicles
(SUV)

25 nm

22 - 50 nm

15 - 30 nm

Intermediate-sized
unilamellar vesicle (IUV)

100 - 200 nm

nd

nd

>60 nm

100 - 200

Large unilamellar vesicle
(LUV)
*nd = not determined

500 nm

79

(a)

(b)

Figure 3.9. Comparison of the AFM images of (a) the pure sphingomyelin from this study
compared to (b) an image of pure phosphatidylcholine vesicles taken from Z.V. Leonenko, A.
Cornini, D.T.Cramb, Biochimica et Biophysica Acta (2000).36b Both vesicles were prepared by
sonication technique from dry film. The Z-height in (a) is approximated as the vesicle diameter.
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detergent concentration. The vesicle preparation with 16 mM Triton X-100 amount produced an
image with a regular clustered molecular array of non-rounded particles. Close observation of
the image revealed stacked round particles which may correspond to clustered micelles.
The Triton X-100 evidently solubilizes the vesicles to produce non-uniform and uniform
shape distributions. The images of vesicles prepared with experimental levels of metal and
buffer are unavailable due to the difficulty in acquiring data on AFM samples with high salt
content, e.g., cerium(IV) ammonium nitrate.
Phosphate determination of metal-assisted hydrolysis of pure sphingomyelin at 60 °C.
A panel of twelve, bi-, tri-, and tetravalent metals metals were each tested for their
comparative abilities to hydrolyze the phosphate ester bond of pure and Triton X-100 solubilized
sphingomyelin vesicles to release phosphocholine and/or choline products.

Following this

hydrolytic cleavage, the released product may undergo secondary cleavage of the remaining
mono-phosphate bond which occurs at a much lower rate as evidenced by the low hydrolysis
percentages quantified by the inorganic phosphate assay. The multiple trials of the metalassisted hydrolysis of sphingomyelin preparations at 60 °C were assayed for inorganic phosphate
concentrations at µmolar levels. The data for each metal is plotted in Figure 3.10 as a 3D
histogram and listed in Table 3.3. The histogram shows a comparison of the percent hydrolysis
by each metal at pH 4.8 and pH 7 (x-axis) as a function of increasing amounts of Triton X-100
(z-axis), and the percent of phosphate released by metal-assisted hydrolysis (y-axis). The inset in
Figure 3.10 shows the results obtained with CeIV since the percentage of phosphate released was
significantly higher in comparison to the other metals.
The ranked metals according to their hydrolytic ability are CeIV > > ZrIV > HfIV ≥ PdII >
all other divalent and trivalent metals. This ranking correlates with the order of hydrolysis
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constants in Figure 3.1 especially for CeIV, ZrIV, HfIV, and PdII where the ability to form a metalOH nucleophile is best facilitated at low pH values. The pH 4.8 data for ZrIV and HfIV show
similar trends with 0 mM < 2 mM < 16 mM Triton X-100 which may indicate a Triton X-100solubilization dependency. The solubilization of a vesicle which has ~40 % of its headgroups
inside the vesicle would expose a larger amount in the micelle structure where all polar
headgroups are exposed. The phosphate concentration data at pH 4.8 for CeIV show a different
order of 0 mM < 16 mM < 2 mM. A 2 mM Triton X-100-solubilized vesicle has more exposed
headgroups because of reduced Columbic repulsion from Triton X-100 interdigitation than the
pure sphingomyelin vesicle where the polar headgroups are closer. For CeIV, ZrIV, and HfIV,
hydrolysis is considerably enhanced at pH 4.8 compared to pH 7. PdII-assisted hydrolysis is the
exception with favorable hydrolysis at pH 7 compared to pH 4.8. Metal speciation may be a
factor affecting the PdII data. For the CeIV, ZrIV, and HfIV metals, the phosphate yields at pH 7
shows less Triton X-100 dependency, with the hydrolysis percentages at 2 mM and 16 mM
having similar yields. The phosphate hydrolysis yields as percentages of the twelve metals are
listed in Table 3.3. The highest yields per metal are 70.7 ≤ 7.1% for CeIV (2 mM Triton X-100,
pH 4.72) > 11.3 ≤ 2.2% for ZrIV (16 mM Triton X-100, pH 4.87) > 2.21 ≤ 0.25% for HfIV (16
mM, pH 4.85), and 2.49 ≤ 0.55% for PdII (2 mM, pH 6.98). Because the highest yields are from
ZrIV, CeIV, and HfIV, these metal ions would be used in further hydrolysis reactions to be
analyzed by the Amplex Red assay which quantitates the hydrolysis products of
phosphocholine and choline. Notwithstanding, the malachite green data showed that CeIV
produced the highest hydrolysis yields of the 12 tested metals. For CeIV, hydrolysis yields at pH
4.8 were statistically higher than hydrolysis yields at pH 7.0, at all Triton X-100 concentrations,
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Figure 3.10. The 3D graph with inset ranks the percentage of hydrolysis by various metals as
measured by the inorganic phosphate release. Solutions were prepared from 2 mM
sphingomyelin, 10 mM metal, 20 mM piperazine (pH 4.8) or HEPES (pH 7.0), and reacted for
20 h, at 60 °C. Phosphate levels were determined by the malachite green assay. The inset shows
the CeIV data with the other metals since the CeIV hydrolysis percentages were much higher.
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Table 3.3. Summary of the twelve metals according to the inorganic phosphate quantification
(µM) for 2 mM sphingomyelin reacted with 10 mM metal at pH 4.8 or pH 7 and 60 °C for 20 h.
Avg.
Metal

pH

CeIV

4.72
7.05

ZrIV

4.87
7.04

HfIV

4.85
7.09

PdII

4.91
6.98

CuII

4.85
7.09

NiII

4.87
7.05

ZnII

4.90
7.13

CoII

4.86
7.10

EuIII

4.90
7.18

Avg. phosphate concentration (µM) ± SD
(% hydrolysis ± SD)
0 mM
2 mM
16 mM
Triton X-100
Triton X-100
Triton X-100
444 ≤ 100
(22.2 ≤ 5.4)
102 ≤ 39
(5.08 ≤ 1.9)
4.36 ≤ 4.4
(0.22 ≤ 0.20)
3.68 ≤ 4.2
(0.18 ≤ 0.2)
0.21 ≤ 1.3
(0.01 ≤ 0.05)
0.13 ≤ 0.8
(0.01 ≤ 0.05)
-1.05 ≤ 2.6
(-0.05 ≤ 0.1)
12.0 ≤ 1.2
(0.60 ≤ 0.05)
3.41 ≤ 1.2
(0.17 ≤ 0.05)
7.16 ≤ 9.1
(0.36≤0.5)
3.86 ≤ 4.6
(0.19≤0.2)
2.65 ≤ 6.0
(0.13≤ 0.3)
3.40 ≤ 3.4
(0.17≤ 0.2)
-0.20 ≤ 0.8
(-0.01≤ 0.05)
4.42 ≤ 1.5
(0.22 ≤ 0.1)
-2.71 ≤ 0.6
(-0.14 ≤ 0.05)
-1.56 ≤ 1.8
(-0.08 ≤ 0.1)
-3.83 ≤ 0.9
(-0.19 ≤ 0.05)

n = number of trials for both pH values

1413 ≤140
(70.7 ≤ 7.1)
332 ≤ 91
(16.6 ≤ 4.6)
112 ≤ 44
(5.62 ≤ 2.2)
60.5 ≤ 28
(3.03≤ 1.4)
16.9 ≤ 3.7
(0.85 ≤ 0.2)
2.74 ≤ 2.9
(0.14≤ 0.2)
-3.16 ≤ 5.0
(-0.16 ≤ 0.2)
50.0 ≤ 11
(2.49 ≤ 0.6)
0.24 ≤ 2.7
(0.01 ≤ 0.1)
-0.25 ≤ 5.7
(-0.01≤ 0.3)
-0.48 ≤ 2.6
(-0.02 ≤ 0.1)
2.65 ≤ 1.0
(0.13 ≤ 0.05)
2.20 ≤ 5.2
(0.11 ≤ 0.3)
1.22 ≤ 4.3
(0.06 ≤ 0.2)
-0.42 ≤ 3.6
(-0.02 ≤ 0.2)
0.00 ≤ 1.5
(0.00 ≤ 0.1)
0.44 ≤ 4.7
(0.02 ≤ 0.2)
-4.04 ≤1.3
(-0.20 ≤ 0.05)

861 ≤ 130
(43.0 ≤ 6.8)
380 ≤ 70
(19.0 ≤ 3.5)
226 ≤ 43.1
(11.3 ≤ 2.2)
61.8 ≤ 25
(3.09 ≤ 1.2)
44.1 ≤ 5.0
(2.21≤ 0.3)
11.6 ≤ 3.8
(0.58 ≤ 0.2)
6.32 ≤ 3.7
(0.32 ≤ 0.2)
27.2 ≤ 4.7
(1.36 ≤ 0.2)
-0.24 ≤ 0.7
(-0.01 ≤ 0.05)
3.46 ≤ 2.2
(0.17 ≤ 0.1)
1.69 ≤ 1.0
(0.08 ≤ 0.05)
-0.96 ≤ 2.7
(-0.05 ≤ 0.13)
1.40 ≤ 2.2
(0.07 ≤ 0.10)
-1.22 ≤ 0.82
(-0.06 ≤ 0.04)
-1.89 ≤ 0.84
(-0.09 ≤ 0.04)
-0.21 ≤ 0.21
(-0.01 ≤ 0.01)
1.33 ≤ 0.9
(0.07 ≤ 0.04)
0.85 ≤ 1.9
(0.04 ≤ 0.1)

n
13-15
11-12
18-19
15-18
6
5-7
2
2
2
2
2
2
2
2
2
2
2
2
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Continued Table 3.3.: Summary of the twelve metals according to the inorganic phosphate
quantification (µM) for 2 mM sphingomyelin reacted with 10 mM metal at pH 4.8 or pH 7 and
60 °C for 20 h.

Metal

LaIII

Avg.
pH
4.91
7.10

YIII

4.93
7.20

YbIII

4.86
7.14

Avg. phosphate concentration (µM) ± SD
(% hydrolysis ± SD)
0 mM
Triton X-100

2 mM
Triton X-100

16 mM
Triton X-100

-7.16 ≤ 0.0
(-0.36 ≤ 0.0)
-4.01 ≤1.5
(-0.20 ≤ 0.07)
-1.01 ≤ 0.0
(-0.05 ≤ 0.0)
-6.21 ≤ 0.8
(-0.31 ≤ 0.04)
-3.96 ≤ 1.7
(-0.20 ≤ 0.08)
-2.13 ≤ 2.3
(-0.11 ≤ 0.1)

-1.26 ≤ 0.8
(-0.06 ≤ 0.05)
-1.69 ≤ 1.1
(-0.08 ≤ 0.05)
-0.20 ≤ 1.6
(-0.01 ≤ 0.08)
-2.00 ≤ 1.8
(-0.10 ≤ 0.1)
-0.42 ≤ 0.2
(-0.02 ≤ 0.01)
-2.13 ≤ 1.7
(-0.11≤ 0.1)

-1.05 ≤ 1.5
(-0.05 ≤ 0.07)
0.42 ≤ 1.3
(0.02 ≤ 0.06)
1.01 ≤ 0.0
(0.05 ≤ 0.0)
0.20 ≤ 2.2
(0.01 ≤ 0.1)
-0.42 ≤ 0.4
(-0.02 ≤ 0.02)
3.19 ≤ 0.85
(0.16 ≤ 0.04)

n = number of trials for both pH values

n

2
2
2
2
2
2
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Figure 3.11. The histogram of zirconocene dichloride and ZrCl4-assisted hydrolysis of
sphingomyelin at pH 4.8 and pH 7 with the hydrolysis yields calculated from phosphate
concentrations. Samples were prepared with 2 mM sphingomyelin, 10 mM metal, and 20 mM
buffer at pH 4.8 or 7 and reacted at 60 °C for 20 h. The zirconocene dichloride experiments
were conducted over 5 trials. The ZrCl4 experiments were conducted over 15-19 trials.
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Figure 3.12. Graph shows the comparison of sphingomyelin hydrolysis yields produced by three
metals as measured by total phosphocholine plus choline and total choline. Hydrolysis
percentages are for 2 mM sphingomyelin, 10 mM metal, 20 mM piperazine buffer (pH 4.8) or
HEPES buffer (pH 7.0) and 0, 2, or 16 mM Triton X-100 treated at 60 °C for 20 h. For ZrIV and
CeIV, n = 7, for HfIV, n = 3, where n = number of trials.
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Table 3.4. Summary of the percentage hydrolysis from total phosphocholine plus choline
concentrations and the choline-only concentrations for ZrIV, HfIV, and CeIV metal-assisted
hydrolysis for 2 mM sphingomyelin reacted with 10 mM metal at pH 4.8 or pH 7 and 60 °C for
20 h. The results are shown in Figure 3.12.

Metal
ZrIV

pH
4.8
7

HfIV

4.8
7

CeIV

4.8
7

Percentage Hydrolysis for Total Phosphocholine plus Choline
Concentrations, Avg ± SD
(Percentage Hydrolysis for Choline-only Concentrations, Avg ± SD)
0 mM
2 mM
16 mM
Triton X-100
Triton X-100
Triton X-100
2.33 ≤ 0.27
19.3 ≤ 2.8
73.0 ≤ 7.6
(1.17 ≤ 0.33)
(13.6 ≤ 0.69)
(51.1 ≤ 2.9)
2.50 ≤ 0.26
17.4 ≤ 2.3
61.9 ≤ 3.3
(1.58 ≤ 0.27)
(16.6 ≤ 1.3)
(47.6 ≤ 5.4)
1.38 ≤ 0.04
9.40 ≤ 0.71
33.2 ≤ 4.8
(0.74 ≤ 0.05)
(7.75 ≤ 0.28)
(26.2 ≤ 0.87)
4.53 ≤ 0.71
23.3 ≤ 1.3
1.13 ≤ 0.18
(1.20 ≤ 0.57)
(3.60 ≤ 0.14)
(20.6 ≤ 2.5)
81.2 ≤ 5.8
88.7 ≤ 6.4
56.8 ≤ 3.1
(54.4 ≤ 3.8)
(81.3 ≤ 6.8)
(83.8 ≤ 4.1)
9.43 ≤ 1.6
30.0 ≤ 2.2
47.6 ≤ 7.3
(7.58 ≤ 1.3)
(24.6 ≤ 5.0)
(44.8 ≤ 5.4)

n
7
7
3
3
7
7
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with the highest cleavage levels being produced at pH 4.8 in the presence of 2 mM Triton X-100,
a concentration of surfactant which would be expected to produce mixed sphingomyelin vesicles.
The histogram in Figure 3.11 compares the percent hydrolysis as determined by
phosphate assay results for zirconocene dichloride and ZrCl4 in order to compare two ZrIV
complexes. Zirconocene dichloride is a non-toxic metallocene which has been used safely in
clinical trials.37 The data at pH 4.8 for both metals show a similar Triton X-100-solubilization
dependencies as the percentage hydrolysis for 0 mM < 2 mM < 16 mM Triton X-100 amounts
and are statistically similar. Both data sets at pH 7 shows that 0 mM < 2 mM ≈ 16 mM, and the
zirconocene dichloride yields are slightly higher than ZrCl4. For ZrCl4 and zirconocene
dichloride, reactivity is greater at lysosomal pH (4.8) than at cytosolic (7.0) pH only at 16 mM
Triton X-100, with ZrCl4 showing the highest differential cleavage at pH 4.8.
Quantification of phosphocholine and choline in metal-assisted hydrolysis reactions at 60
°C using an Amplex
 Red method.
The hydrolysis of the phosphate ester bonds of sphingomyelin generates phosphocholine
and choline. The phosphocholine and choline products produced in metal-assisted hydrolysis
reactions were quantified by Amplex Red assay. A novel adaptation of the assay’s enzyme
mix, whereby only the choline product is measureable, allowed differential quantification of the
total phosphocholine plus choline products vs. the choline product (and thus phosphocholine
concentrations indirectly by difference).

Figure 3.12 shows the compilation of results of

multiple sphingomyelin hydrolysis reaction trials at 60 °C for the three metals, ZrIV, HfIV, and
CeIV since these tetravalent metals produced the highest hydrolysis yields in the malachite green
phosphate detection assay (Figure 3.10). The Amplex Red data show that the order of metal
reactivity for the hydrolysis of 2 mM sphingomyelin in the presence of 10 mM metal and 20 mM
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buffer at 60 °C for 20 h is CeIV > ZrIV > HfIV (Figure 3.12). This trend correlates with the pKa
order of metals and their ability to form a hydroxide-bound metal complex which serves as a
nucleophile in the phosphate ester hydrolysis reaction (Figure 3.1).
The pure sphingomyelin vesicles were solubilized by increasing amounts (0, 2, and 16
mM) of Triton X-100. For all three metals, the increased Triton X-100 levels were correlated to
higher yields presumably due to the bilayer to monolayer transition with increased phosphate
ester bond exposure on the exovesicular layer of the liposome. Also, the increased Triton X-100
interdigitation within the vesicle bilayer reduces columbic repulsion so that the metal-OH
nucleophile may react in a more facile fashion.
The experiments at each Triton X-100 were performed at two different pH values which
simulate the lysosomal pH 4.8 and the cytosolic pH 7.0 at 60 °C. The maximum hydrolysis
yields per metal and per Triton X-100 amount as measured by the total phosphocholine and
choline assay are 73.0 ≤ 7.55% for ZrIV (16 mM Triton X-100 , pH 4.8), 33.2 ≤ 4.77% for HfIV
(16 mM Triton X-100, pH 4.8), and 88.7 ≤ 6.40% for CeIV (16 mM Triton X-100, pH 4.8).
The data in Figure 3.12 for ZrIV and HfIV show that the hydrolysis yields at 60 °C are not
significantly enhanced at lysosomal pH since the ratios of yields pH 4.8: pH 7.0 for ZrIV are 0.93
(0 mM), 1.11 (2 mM), 1.18 (16 mM); and for HfIV are 1.21 (0 mM), 2.07 (2 mM), 1.42 (16 mM).
A value < 1 signifies no pH enhancement of hydrolysis in lysosome compared to cytosol, while
a value > 1 shows reactivity that is has greater yields in the lysosome. In contrast, CeIV shows a
significant enhancement in yields at lysosomal pH compared to cytosolic pH at 60 °C, with ratio
of yields (pH 4.8: pH 7) of 6.02 (0 mM), 2.70 (2 mM), and 1.86 (16 mM).
The novel, modified choline-only assay is plotted alongside the total phosphocholine and
choline results. Choline differentiation from the phosphocholine yields is important factor in the
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determination of the regioselectivity of a metal-hydrolytic agent and its ability to mimic the acid
sphingomyelinase enzyme although this neglects the dephosphorylation of the phosphocholine
product which could occur as a secondary metal-assisted hydrolysis reaction. The choline
product produced is approximately the same at pH 4.8 and pH 7 for ZrIV and HfIV while CeIV
shows much more choline produced much more at pH 4.8 than at pH 7. For ZrIV, HfIV, and CeIV
metals, the choline at pH 4.8 is less than the total phosphocholine plus choline amounts and
ranges from 50-70 % for ZrIV, 54-82% for HfIV, and 95-100 % for CeIV of the total
phosphocholine plus choline yields. The choline at pH 7 is also less than the total
phosphocholine plus choline amounts and ranges from 63-95% for ZrIV, 79-106% for HfIV, and
80-94% for CeIV of the total phosphocholine plus choline yields. The predominance of choline
product may originate from two pathways: 1) the metal preferentially hydrolyzes the choline side
of the phosphate ester bond of sphingomyelin due to steric effects, or 2) phosphocholine
hydrolysis product is hydrolyzed to choline and inorganic phosphate due to a labile phosphate,
although the inorganic phosphate levels determined in the malachite green assay do not account
for the differences between phosphocholine and choline.

For CeIV, the choline yields are

approximately the same yields as the total which indicates either very little phosphocholine
product or an advanced degree of dephosphorylation of the phosphocholine product.
Cholesterol effects on sphingomyelin vesicles at 37 °C and at 60 °C.
Cholesterol plays a key role in phospholipid membranes because it modulates the
structure, dynamics, and function of the bilayer.

Cholesterol increases the cross-sectional

packing of the phospholipid bilayer with denser packing.

Since cholesterol induces tighter

packing within the bilayer and thus higher columbic repulsion within the polar headgroup region
of sphingomyelin vesicles, the predicted result is less metal-polar headgroup interaction and,
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consequently, reduced hydrolysis.23,24,28,32j-k Niemann-Pick cells show elevated cholesterol in
the liver and spleen cells that cause a characteristic foamy appearance. Lipid compositional
analysis of a Niemann-Pick Type A patient’s cerebral cortex showed 27.6 µmol/g wet wt.
cholesterol with 31.9 µmol/g sphingomyelin compared to the control patient’s cerebral cortex
which had 24 µmol/g wet wt. cholesterol and 4.1 µmol/g wet wt. sphingomyelin. The cerebral
white matter show 37 µmol/g wet wt. cholesterol and 28.3 µmol/g wet wt. sphingomyelin
compared to the control patient’s cerebral white matter which had 118.5 µmol/g wet wt.
cholesterol and 112.1 µmol/g wet wt. sphingomyelin.38,33b Given these elevated cholesterol
levels, sphingomyelin vesicles with 50 mole % cholesterol were hydrolyzed in the presence of 10
mM metal and 20 mM buffer to represent a balance between normal physiological cholesterol
levels and high levels observed in Niemann-Pick Type A patients.
Figure 3.13 shows several trends for ZrIV including a large reduction in hydrolytic yields
when cholesterol is present, the similar yields for both pH 4.8 and 7.0 as observed in the use of
pure sphingomyelin without cholesterol (Figure 3.12), and the total phosphocholine plus choline
amounts are slightly greater than the choline. In Figure 3.13, vesicles with sphingomyelin and 50
mol % cholesterol were hydrolyzed with ZrIV at both 60 °C and 37 °C for 20 h. The overall
yields have decreased by half compared to the reactions without cholesterol. In addition, yield
percentages as a function of Triton X-100 concentration follow the general trends of the noncholesterol data for both pH 4.8 and 7 with 0 mM < 2 mM < < 16 mM. The Figure 3.13 (a)
shows the maximum ZrIV-assisted yields at 60 °C: 31.4 ≤ 1.3% (16 mM Triton X-100, pH 4.8)
and 28.6 ≤ 1.1% (16 mM Triton X-100, pH 7) compared to 73.0 ≤ 7.6% (16 mM) at pH 4.8 and
61.9 ≤ 3.3% (16 mM) at pH 7 without cholesterol. (Figure 3.12 and Table 3.4) For the 60 °C
data, cholesterol reduces the hydrolytic yields by 2-4 times. The hydrolysis yields at 37 °C are
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much lower than the 60 °C. The overall yields at 37 °C in Figure 3.13 (b) show a maximum at
1.13 ≤ 0.49% (16 mM Triton X-100, pH 4.8) and at 1.02 ≤ 0.09% (16 mM Triton X-100, pH
7). The trends for the hydrolysis yield ratios at lysosomal pH 4.8 to cytosolic pH 7.0 are similar
to the pure sphingomyelin vesicles without cholesterol at 60 °C where no pH advantage at pH
4.8 or 7 occurs in hydrolysis (Figure 3.12 and Figure 3.13).
The trends in hydrolytic yields as determined by phosphate concentrations are similar to
the total phosphocholine plus choline yields except at 16 mM, pH 7 which shows a slightly lower
phosphate yield than expected (Figure 3.13).
The cholesterol sphingomyelin reactions were then repeated for CeIV. Figure 3.14 (a-d)
plots the hydrolysis yields for CeIV-assisted sphingomyelin vesicles that contain 50 mol %
cholesterol. Figure 3.14 (a-d) shows several new trends: the addition of cholesterol reduces the
hydrolysis yields to a lesser degree than ZrIV (Figure 3.13), yields at pH 4.8 are reduced to a
greater extent than at 7.0, and the maximum 60 ° C hydrolysis yields are highest at 2 mM Triton
X-100. Unlike the ZrIV data (37 °C and 60 °C; Figure 3.13), the maximum yields at 60 °C shown
in Figure 3.14 (a) occur at 2 mM Triton X-100 for both pH 4.8 and 7 with 69.4 ≤ 6.7 % (2 mM,
pH 4.8) and 37.4 ≤ 9.2% (2 mM, pH 7) compared to the non-cholesterol hydrolysis percentages
of 81.2 ≤ 5.8% (2 mM, pH 4.8) and 30.0 ≤ 2.2% (2 mM, pH 7). The overall Triton X-100
rankings at 60 °C show that pH 4.8 and pH 7.0 trends are very different: 0 mM < 16 mM < 2
mM (pH 4.8) and 0 mM ~ 2 mM ~ 16 mM (pH 7.0). The pH 7 hydrolysis yields are elevated
compared to Figure 3.12 where there was a dramatic difference between pH 4.8 and pH 7 in the
non-cholesterol data. As seen in Table 3.5 for CeIV metal, the 0 and 2 mM Triton X-100
hydrolysis yields at pH 7 show reversed trends with the 50 mol % cholesterol reactions
producing higher yields with cholesterol than without. Overall, the majority of the 60 °C data
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shows between 1-2 times lower hydrolytic yields with cholesterol except for the two pH 7
reactions which are 1 and 3.5 times greater. The 37 °C hydrolysis yields in Figure 3.14 (b) show
maxima at 16 mM Triton X-100 for both pH 4.8 and 7.0 with 21.3 ≤ 1.4% (16 mM Triton X100, pH 4.8) and 11.3 ≤ 0.51% (16 mM Triton X-100, pH 7). The phosphate assay shows
similar trends in Figure 3.14 (c-d) with 60 °C hydrolysis reactions producing maximum yields at
2 mM Triton X-100, and 37 °C hydrolysis reactions producing maximum yields at 16 mM Triton
X-100. The pH 4.8 yields show a slight increase over the pH 7.0 yields at both 37 °C and 60 °C.
The comparison of 60 °C hydrolysis yields for sphingomyelin vesicles with 0 % (Figure
3.12) and 50 mol % cholesterol (Figures 3.13 and 3.14 and Table 3.5) shows less attenuation in
hydrolytic yields for CeIV than for ZrIV. For the majority of the CeIV data, the presence of the
cholesterol reduces yields by 1.17 - 1.82 times excluding the above mentioned pH 7.0 reactions.
Time course studies of the metal-assisted hydrolysis reactions of sphingomyelin.
A major emphasis of this study is to investigate differential levels of hydrolysis at pH 4.8
versus pH 7 to assess the physiological differences that may occur between the lysosomal and
the cytosolic pH for a potential metal-based therapeutic drug. Figure 3.15 (a-b) plots the ratio of
ZrIV and CeIV hydrolysis yields (pH 4.8/pH 7.0) from the total phosphocholine plus choline assay
results at pH 4.8 and pH 7. A ratio greater than one indicates that hydrolysis is favored at pH 4.8
over pH 7 which may predict higher reactivity in the lysosome compared to the cytosol in a
cellular environment. The majority of the ZrIV plots in Figure 3.15 show that at 37 °C and 60 °C,
the maximum ratio, and thus enzyme mimicry, occurs at 4 h and decreases slightly to a constant
level.
For ZrIV at 0 mM Triton X-100 and 37 °C, this pH 4.8 advantage is most dramatic since
the ratio at t = 4 h approaches five (Figure 3.15). The results illustrate that ZrIV hydrolysis of
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(a)

(b)

(c)

(d)

Figure 3.13. Yields produced by ZrIV hydrolysis of sphingomyelin with 50 mole % cholesterol
at 60 °C and 37 °C. The percentage hydrolysis of total phosphocholine plus choline or the
modified choline-only assays are shown in (a-b) while the percentage hydrolysis as calculated
from free inorganic phosphate are shown in (c-d). Samples prepared with 2 mM sphingomyelin,
10 mM ZrCl4, 20 mM piperazine (pH 4.8) or HEPES (pH 7.0), and 1 mM cholesterol were
reacted at 60 °C and 37 °C for 20 h. The number of trials = 3.
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(a)

(c)

(b)

(d)

Figure 3.14. Yields produced by CeIV hydrolysis of sphingomyelin with 50 mole % cholesterol
at 60 °C and 37 °C. The percentage hydrolysis of total phosphocholine plus choline or the
modified choline-only assays are shown in (a-b) while the percentage hydrolysis as calculated
from free inorganic phosphate are shown in (c-d). Samples prepared with 2 mM sphingomyelin,
10 mM CeIV ammonium nitrate, 20 mM piperazine (pH 4.8) or HEPES (pH 7.0), and 1 mM
cholesterol were reacted at 60 °C and 37 °C for 20 h. The number of trials = 3.
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Table 3.5. Percent hydrolysis yields of total phosphocholine plus choline for sphingomyelin
reacted at 60 °C with 0 and 50 mol % cholesterol for ZrIV and CeIV.
Hydrolysis percentage
average ± SD %
Metal

Triton X-100

pH

0 mol % cholesterol

50 mol % cholesterol

4.8
7
4.8
7
4.8
7
4.8
7
4.8
7
4.8
7

2.33 ≤ 0.27
2.50 ≤ 0.26
19.3 ≤ 2.8
17.4 ≤ 2.3
73.0 ≤ 7.6
61.9 ≤ 3.3
56.8 ≤ 3.1
9.43 ≤ 1.6
81.2 ≤ 5.8
30.0 ≤ 2.2
88.7 ≤ 6.4
47.6 ≤ 7.3

0.57 ≤ 0.01
1.2 ≤ 0.03
8.8 ≤ 0.2
5.1 ≤ 0.7
31.4 ≤1.3
28.6 ≤ 1.1
39.9 ≤ 7.0
33.8 ≤ 9.4
69.4 ≤ 6.7
37.4 ≤ 9.2
59.7 ≤ 3.6
26.1 ≤ 6.6

(mM)
ZrIV

0
2
16

CeIV

0
2
16
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(a)

(b)

Figure 3.15. Time course experiments showing ratios of pH 4.8 total phosphocholine plus
choline yields to pH 7.0 total phosphocholine plus choline yields at 37 °C and 60 °C as a
function of Triton X-100 concentration. Samples were prepared with 2 mM sphingomyelin, 10
mM metal ZrCl4 (shown in (a)) or Ce(NH4)2(NO3)6 (shown in (b)), 20 mM piperazine or HEPES
were reacted at 37 °C and 60 °C for 20 h. Ratios were taken from the total phosphocholine and
choline results of the Amplex Red-based assay.The number of trials = 4. CeIV and ZrIV yields
are plotted in Figures 3.17 and 3.20.
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(a)

(b)

Figure 3.16. Time course experiments showing ratios of pH 4.8 choline yields to pH 7.0 choline
yields at 37 °C and 60 °C as a function of Triton X-100 concentration. Samples prepared with 2
mM sphingomyelin, 10 mM metal (ZrCl4 shown in (a)) or (Ce(NH4)2(NO3)6 shown in (b)), 20
mM piperazine or HEPES were reacted at 37 °C and 60 °C for 20 h. Ratios were taken from the
choline results of the Amplex Red-based assay. The plot in (a) only shows the 60 °C data since
the 37 °C data is below detection. The number of trials = 4. CeIV and ZrIV yields are in Figures
3.18 and 3.21.
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pure sphingomyelin vesicles is significantly enhanced at lysosomal pH at physiological
termperature. The ratios at 2 and 16 mM Triton X-100 for 37 °C are also greater than one. At the
higher temperature of 60 °C, the ratios at 0, 2, and 16 mM Triton X-100 for ZrIV hydrolysis are
approximately one which indicates no pH preference.
While the overall yields of CeIV are higher than ZrIV for 0, 2, and 16 mM Triton X-100,
the pH advantage at lysosomal pH 4.8 is not significant. At 60 °C, the pH ratio of yields shows a
slight advantage especially at 4 h, but levels off to a ratio of one at longer reaction times. The 37
°C data show that the pH ratio of yields at 0, 2 and 16 mM are approximately one.
Figure 3.16 shows a corollary graph to the previous Figure 3.15 where the pH ratio of the
modified choline-only assay yields are plotted. Similar trends in the ZrIV data are observed
compared to the previous figure except that the 37 °C, 0 mM Triton X-100 data is negligible.
For the CeIV plots, only the 60 °C shows a pH 4.8 advantage with ratios slightly greater than 1,
while the 37 °C shows no pH advantage since the ratios are approximately equal to unity.
Percentage hydrolysis by total phosphocholine plus choline, modified choline-only, and
phosphate assays at 37 °C and 60 °C.
CeIV-assisted and ZrIV-assisted hydrolysis. The hydrolysis yields used to produce ratios
shown in Figures 3.15 and 3.16 are shown in Figures 3.17, 3.18, 3.19, 3.20, 3.21, and 3.22. The
percentage of hydrolysis at 37 °C and 60 °C as calculated by the total phosphocholine plus
choline assay is on the y- axis of each figure (Figure 3.17 and 3.20) or the modified choline-only
assay is on the y-axis of each figure (Figure 3.18 and 3.21). Figures 3.17 and 3.18 show the
progression of hydrolysis reactions of 2 mM of pure sphingomyelin vesicles as well as
sphingomyelin solubilized by 0, 2, or 16 mM amounts of Triton X-100 detergent in the presence
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of 10 mM cerium(IV) ammonium nitrate and 20 mM piperazine (pH 4.8) or HEPES (pH 7). The
pH differences between the hydrolysis percentages at 37 °C and 60 °C at 20 h are fully discussed
in a later section and presented in Table 3.11. At 37 °C, the pH 4.8 and 7 data almost overlapped
with differences < 10 % for the total phosphocholine plus choline assay (Figure 3.17). The 60 °C
data show that at pH 4.8, the hydrolysis is higher than at pH 7 by ~25 - 30% at all timpoints.
Thus, the extreme pH-dependence (pH 4.8 > pH 7.0) in hydrolytic yields demonstrated at 60 ±C
disappears at 37 ±C. The early timepoints of 4 h and 8 h show slower kinetics in the presence of
0 mM Triton X-100 (pure vesicle) compared to the 16 mM (micelles). Figure 3.19 shows the
phosphate release during the reaction.
Figure 3.20 and 3.21 show the progression of the hydrolysis reactions of 2 mM pure
sphingomyelin vesicles at 0, 2, and 16 mM amounts of Triton X-100 detergent in the presence of
10 mM ZrCl4 and 20 mM piperazine (pH 4.8) or HEPES (pH 7). At 37 °C (Figure 3.20 (a) and
Figure 3.21 (b)), the percentage of hydrolysis at 0 and 2 mM is barely detectable while 16 mM
Triton X-100 levels show pH 4.8 > pH 7. At 60 °C (Figure 3.20 (b) and 3.21 (b), the pH 4.8 and
7 slopes almost overlap. The phosphate amounts in Figure 3.22 are approximately 10 % of the
total phosphocholine plus choline results.
This data demonstrate that the regioselective hydrolysis by metals at the phosphate ester
bond to release phosphocholine is not favored in this cleavage reaction since the high choline
percentages indicate that the metals hydrolyze the polar side of the molecule to release choline.
The choline side of the phosphate ester bond also represents less steric hindrance. The acid
sphingomyelinase enzyme solely releases phosphocholine in the lysosomes. However, the metalassisted hydrolysis of the primary product of phosphocholine to release inorganic phosphate and
a secondary product of choline is a very likely possibility due to the phosphate and choline levels
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detected in the hydrolysis of the phosphocholine positive control. This being said, the MALDI
mass spectra in Figure 3.23 show the increase of choline in a metal-assisted hydrolysis of
phosphocholine.
Estimated half-lives of ZrIV- and CeIV-assisted reactions at 60 °C and 37 °C. Table
3.10 shows the estimated half lives (t½) in units of hours for the reactions shown in Figures 3.17 3.22 according to the total phosphocholine plus choline assay and the choline assay results. The
assays contained the four datapoints from t = 0, 4, 8, and 20 h from which the data was
approximated. For each of the CeIV or ZrIV reactions, the half-lives were estimated from multiple
time course experiments with linear plots of the natural log of the remaining unreacted
sphingomyelin (ln P0 – Ptime) as a function of time according to a slope equation criteria that
correlation coefficient of R be ≥ 0.98. Plots which produced correlation coefficients less than
0.98 or whose reaction was too slow and produced extremely long half-lives were listed in the
table as “nd” for “not determined”. According to the linear fit slope equations from each
experiment’s plots, the (-) slope = k and t1/2 = 0.693/k values were calculated to obtain the halflife.
The half-life is the inverval required for the quantity to decay to half of its initial value.
Since the total experimental times were 20 h, only the 60 °C data for CeIV (0, 2, and 16 mM
Triton X-100) and ZrIV data (16 mM only) have half-lives less than the 20 h time cut-off. Table
3.10. shows that at 60 °C data, CeIV had the shortest half-lives with a range of 5 h ≤ 0.5 (total
phosphocholine plus choline assay, 2 mM Triton X-100, pH 4.86) to 19 h ≤ 1 (total
phosphocholine plus choline assay, 0 mM Triton X-100, pH 6.95). Also at 60 °C, the half-lives
for ZrIV ranged from 7 h ≤ 0.5 (total phosphocholine plus choline assay, 16 mM, pH 7.07) to 300
h ≤ 1 (total phosphocholine plus choline assay, 0 mM Triton X-100, pH 4.84). For CeIV, the
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shortest half-life of 5 h (total phosphocholine plus choline assay, 2 mM Triton X-100, pH 4.86,
60 °C) represents four half-lives in a total 20 h reaction time where 93.8 % of the sphingomyelin
is reacted. For ZrIV, the shortest half-life of 7 h (total phosphocholine plus choline assay, 16 mM
Triton X-100, pH 7.07, 60 °C) represents approximately three half-lives in a 20 h reaction time
where 87.5% of the sphingomyelin is reacted. At 37 °C, the CeIV had the shortest half-lives of 20
h ≤ 0.5 (total phosphocholine plus choline assay, 16 mM Triton X-100, pH 7.06) to 80 h ≤ 1
(total phosphocholine plus choline assay, 0 mM Triton X-100, pH 4.78 and pH 7.02). The
estimated half-lives for ZrIV at 37 °C range from 100 h ≤ 1 (total phosphocholine plus choline
assay, 16 mM Triton X-100, pH 4.90) to 7000 h ≤ 2 (0 mM Triton X-100, pH 7.04). The plots
from the choline assay produced half-lives which lagged the half-lives calculated from the total
phosphocholine plus choline assay.
MALDI spectra for phosphocholine.
Figure 3.23 shows the MALDI mass spectra of the ZrIV-assisted hydrolysis of
phosphocholine used as a positive control. A total of 2 mM phosphocholine was reacted with 10
mM ZrCl4 at 0, 5, and 23 h timepoints at 60 °C, 20 mM Tris buffer, pH 4.8. The experiment was
conducted to validate the dephosphorylation of the phosphocholine molecule to produce a
choline product. Only the mass range of 90 - 140 Da is shown in order to reduce the complexity
of the spectra with other unrelated mass peaks such as solvent cluster peaks. The Tris buffer
mass peak at m/z 122 is present in a constant 20 mM concentration and serves as a reaction
surrogate been subjected to the experimental conditions and treatments as the phosphocholine
analyte. At 0 h, a small choline product appears at < 10%. Its presence may be attributed to
either pre-reaction degradation of phosphocholine or a choline impurity. The choline mass peak
intensifies from 35% (5 h) to 100% (23 h) of the spectra as a product of the phosphocholine
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hydrolysis. While the MALDI analysis variability in peak heights prevents strict quantification,
an approximation of the reaction progress of the metal-assisted dephosphorylation can be made.
pH drift of the metal-assisted experiments.
The piperazine and HEPES buffers used in the experiments were chosen because their
pKa values indicated potential buffering in the pH regions that simulate lysosomal (pH 4.8) and
cytosolic (pH 7.0). The pKa of piperazine is 5.33 with a buffer range of 5 - 6. The pKa of HEPES
is 7.5 with a buffer region of 6.8 to 8.2. Additionally, the piperazine buffer does not contain a
carboxylate group, a reactive functional group to the oxophilic metals, like the majority of the
buffers in the pH 3 - 5 range. Table 3.11 shows the average pH and the DpH values for all of the
experiments combined in order to see the extent of the pH drifts within the 20 h experiments
conducted in this study. The pH drift value was calculated from the difference in pH at t = 0 h
and t = 20 h (0 h – 20 h) which is equal to the DpH values. The lysosomal pH 4.8 data in the
table shows that ZrIV- or HfIV-assisted experiments showed good pH control with pH drift from 0.02 to 0.03 from the original 0 h pH setpoint at 60 °C (ZrIV and HfIV) and 0.01 to 0.1 at 37 °C
(ZrIV only). The zirconocene and non-metal controls showed similar pH drifts. The CeIV reaction
pH showed higher pH drifts in the range of 0.42 to 0.48 at 60 °C and 0.17 to 0.37 at 37 °C. The
phosphocholine hydrolysis experiments showed the highest pH drift, 0.53 at 60 °C. Since the pH
drift in the piperazine-buffered experiments is approximately correlated with hydrolysis yields,
i.e., the greater the hydrolysis, the greater the pH drift, the proton flux generated during the
hydrolysis was greater than the buffering capacity.
The buffering at pH 7 showed less drift in pH during the reactions. For the cytosolic pH 7
experiments buffered by HEPES, the pH drift of ZrIV or HfIV experiments ranged from -0.03 to
0.02 at 60 °C (ZrIV and HfIV) and -0.05 to 0.03 at 37 °C (ZrIV only).
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(a)

(b)

Figure 3.17. The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM CeIV
ammonium nitrate at pH 4.8 or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as
calculated by total phosphocholine plus choline concentrations. The graphs in column (a) are
results at 37 °C and the graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is
the percentage of hydrolysis calculated from the Amplex Red assay results of total
phosphocholine and choline. Corresponding yield ratios are in Figure 3.15 (b).
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(a)

(b)

Figure 3.18. The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM CeIV
ammonium nitrate at pH 4.8 or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as
calculated by choline concentrations. The graphs in column (a) are results at 37 °C and the
graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage of
hydrolysis calculated from the Amplex Red assay results of choline. Corresponding yield ratios
are in Figure 3.16 (b).
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(a)

(b)

Figure 3.19. The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM CeIV
ammonium nitrate at pH 4.8 or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as
calculated by inorganic phosphate concentrations. The graphs in column (a) are results at 37 °C
and the graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage
of hydrolysis calculated from the malachite green assay for phosphate.
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(a)

(b)

Figure 3.20. The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM ZrCl4 at pH 4.8
or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as calculated by total
phosphocholine plus choline concentrations. The graphs in column (a) are results at 37 °C and
the graphs in column (b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage of
hydrolysis calculated from the Amplex Red assay results of phosphocholine and choline.
Corresponding yield ratios are in Figure 3.15 (a).
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(a)

(b)

Figure 3.21. The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM ZrCl4 at pH 4.8
or pH 7 at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as calculated by choline concentrations.
The graphs in column (a) are results at 37 °C and the graphs in column (b) are the results at 60
°C. For (a) and (b), the y-axis is the percentage of hydrolysis calculated from the Amplex Red
assay results of choline. Corresponding yield ratios are in Figure 3.16 (a).

109

(a)

(b)

Figure 3.22. The percentage of hydrolysis of 2 mM sphingomyelin with 10 mM ZrCl4 at pH 4.8
or pH 7 and at 37 °C or 60 °C at 0, 4, 8, and 20 h timepoints as calculated by inorganic
phosphate concentrations. The graphs in column (a) are results at 37 °C and the graphs in column
(b) are the results at 60 °C. For (a) and (b), the y-axis is the percentage of hydrolysis calculated
from the malachite green assay for phosphate.
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Table 3.6. The percentage hydrolysis by total phosphocholine plus choline concentrations (or
choline-only concentrations) for the reaction progress of the ZrIV metal-assisted hydrolysis of
sphingomyelin with four timepoints.
Metal Triton Temp.
ion
X-100 (°°C)
(mM)

ZrIV

0

37

Time
(h)

0
4
8
20

60

0
4
8
20

2

37

0
4
8
20

60

0
4
8
20

Percentage Hydrolysis
at pH 4.8

Percentage Hydrolysis
at pH 7

Avg. ± SD %
of total phosphocholine plus choline
(Avg. ± SD
of choline only)

Avg. ± SD %
of total phosphocholine plus choline
(Avg. ± SD
of choline only)

0.00 ≤ 0.00
(0.00 ≤ 0.00)
0.23 ≤ 0.04
(0.05 ≤ 0.00)
0.23 ≤ 0.11
(-0.10 ≤ 0.00)
0.50 ≤ 0.21
(-0.10 ≤ 0.00)
0.00 ≤ 0.00
(0.00 ≤ 0.00)
0.71 ≤ 0.13
(0.46 ≤ 0.01)
1.08 ≤ 0.07
(0.54 ≤0.05)
4.50 ≤ 0.23
(3.16 ≤ 0.54)
0.00 ≤ 0.00
(0.00 ≤ 0.00)
0.71 ≤ 0.06
(0.46 ≤ 0.00)
1.07 ≤0.30
(0.42 ≤ 0.03)
2.20 ≤ 0.40
(1.55 ≤ 0.39)
0.00 ≤ 0.00
(0.00 ≤ 0.00)
10.4 ≤ 0.55
(5.91 ≤ 0.12)
17.4 ≤ 2.1
(12.1 ≤ 1.5)
44.3 ≤ 6.6
(36.0 ≤ 7.6)

0.00 ≤ 0.00
(0.00 ≤ 0.00)
0.04 ≤ 0.05
(-0.20 ≤ 0.00)
0.10 ≤ 0.03
(0.00 ≤ 0.00)
0.23 ≤ 0.02
(0.00 ≤ 0.00)
0.00 ≤ 0.00
(0.00 ≤ 0.00)
0.87 ≤ 0.17
(0.65 ≤ 0.14)
2.80 ≤ 0.02
(2.05 ≤ 0.42)
5.60 ≤0.71
(5.03 ≤1.2)
0.00 ≤ 0.00
(0.00 ≤0.00)
0.28 ≤ 0.05
(0.25 ≤ 0.00)
0.65 ≤ 0.05
(0.46 ≤ 0.02)
1.29 ≤ 0.22
(0.76 ≤ 0.05)
0.00 ≤ 0.00
(0.00 ≤0.00)
6.07 ≤0.04
(4.18 ≤ 0.80)
13.2 ≤ 1.1
(8.62 ≤ 1.3)
33.6 ≤ 5.6
(28.2 ≤ 6.7)
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Continued Table 3.6.: The percentage hydrolysis by total phosphocholine plus choline
concentrations or choline-only concentrations for the reaction progress of the ZrIV metal-assisted
hydrolysis of sphingomyelin with four timepoints.
Metal
ion

ZrIV

Triton
X-100
(mM)

Temp.
(°°C)

Time
(h)

Avg. ± SD %
of total phosphocholine
choline
(Avg. ± SD
of choline only)

16

37

0
4
8
20

60

0
4
8
20

Percentage Hydrolysis
at pH 7

Percentage Hydrolysis
at pH 4.8

0.00 ≤ 0.00
(0.00 ≤ 0.00)
2.35 ≤ 0.34
(1.53 ≤ 0.36)
5.00 ≤ 0.45
(3.04 ≤ 0.36)
12.9 ≤ 1.2
(8.30 ≤ 0.90)
0.00 ≤ 0.00
(0.00 ≤ 0.00)
25.3 ≤ 0.92
(15.8 ≤ 0.54)
41.3 ≤ 1.1
(28.6 ≤ 1.3)
80.7 ≤7.4
(62.6 ≤ 7.061)

plus

Avg. ± SD %
of total phosphocholine plus choline
(Avg. ± SD
of choline only)

0.00 ≤ 0.00
(0.00 ≤ 0.00)
1.11 ≤ 0.09
(0.53 ≤ 0.13)
1.49 ≤ 0.04
(1.18 ≤ 0.12)
4.09 ≤ 0.27
(3.02 ≤ 0.35)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
19.3 ≤ 0.6
(14.5 ≤ 0.6)
38.3 ≤ 5.8
(27.8 ≤ 3.8)
84.7 ≤ 6.0
(72.1 ≤ 4.7)
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Table 3.7. The percentage hydrolysis by total phosphocholine plus choline concentrations or
choline-only concentrations for the reaction progress of the CeIV metal-assisted hydrolysis of
sphingomyelin with four timepoints.
Metal

CeIV

Triton Temp.
X-100 (°°C)
(mM)

0

37

Time
(h)

0
4
8
20

60

0
4
8
20

2

37

0
4
8
20

60

0
4
8
20

Percentage Hydrolysis at Percentage Hydrolysis at
pH 7
pH 4.8
Avg. ± SD
of total phosphocholine plus choline
(Avg. ± SD
of choline only)

Avg. ± SD
of total phosphocholine plus choline
(Avg. ± SD
of choline only)

0.00 ≤ 0.00
(0.00 ≤ 0.00)
4.88 ≤ 0.11
(4.36 ≤ 0.55)
8.06 ≤ 1.8
(5.08 ≤ 1.2)
17.0 ≤ 2.1
(17.3 ≤ 1.6)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
39.6 ≤ 4.2
(36.7 ≤ 4.5)
53.9 ≤ 6.1
(49.5 ≤ 9.0)
80.9 ≤ 2.5
(77.6 ≤ 6.0)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
9.75 ≤ 1.5
(9.28 ≤ 1.2)
17.4 ≤ 0.32
(14.3 ≤ 1.6)
31.2 ≤ 0.66
(28.9 ≤ 2.0)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
48.7 ≤ 7.6
(45.6 ≤ 5.8)
69.3 ≤ 3.3
(68.5 ≤ 3.1)
94.2 ≤ 14.1
(91.6 ≤ 11.9)

0.00 ≤ 0.0
(0.00 ≤ 0.0)
5.04 ≤ 1.0
(5.50 ≤ 1.3)
5.26 ≤ 0.34
(4.71 ≤ 0.37)
14.18 ≤ 2.9
(12.3 ≤ 3.0)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
21.1 ≤ 3.4
(20.5 ≤ 3.0)
34.0 ≤ 3.2
(32.3 ≤ 2.0)
52.5 ≤ 7.6
(49.6 ≤ 5.3)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
13.0 ≤ 2.9
(13.3 ≤ 2.8)
22.5 ≤ 1.1
(20.7 ≤ 2.0)
30.1 ≤ 7.4
(29.2 ≤ 6.0)
0.00 ≤ 0.00
(0.00 ≤ 0.00)
32.5 ≤ 0.14
(31.8 ≤ 1.2)
47.1 ≤ 0.58
(46.3 ≤ 0.03)
65.8 ≤ 0.63
(65.2 ≤ 1.1)
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Continued Table 3.7.: The percentage hydrolysis by total phosphocholine plus choline
concentrations or choline-only concentrations for the reaction progress of the CeIV metal-assisted
hydrolysis of sphingomyelin with four timepoints.
Metal

CeIV

Triton Temp.
X-100 (°°C)
(mM)

16

37

Time
(h)

0
4
8
20

60

0
4
8
20

Percentage
pH 4.8

Hydrolysis

at Percentage Hydrolysis at
pH 7

Avg. ± SD
of total phosphocholine plus choline
(Avg. ± SD
of choline only)

Avg. ± SD
of total phosphocholine
choline
(Avg. ± SD
of choline only)

0.00 ≤ 0.0
(0.00 ≤ 0.0)
19.3 ≤ 2.7
(15.6 ≤ 0.90)
31.8 ≤ 4.4
(25.5 ≤ 3.7)
48.2 ≤ 7.6
(47.1 ≤ 3.9)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
63.9 ≤ 9.2
(60.5 ≤7.6)
79.5 ≤ 8.8
(77.9 ≤ 11)
90.5 ≤ 16
(91.2 ≤ 11)

0.00 ≤ 0.0
(0.00 ≤ 0.0)
20.2 ≤ 1.5
(19.9 ≤ 4.4)
40.7 ≤ 3.78
(36.9 ≤3.8)
53.3 ≤ 7.8
(53.3 ≤ 9.4)
0.00 ≤ 0.0
(0.00 ≤ 0.0)
28.6 ≤ 1.9
(28.3 ≤ 5.7)
55.7 ≤ 6.6
(59.8 ≤ 0.22)
71.5 ≤ 13.0
(67.8 ≤ 14)

plus
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Table 3.8. The percentage hydrolysis by phosphate concentrations for the reaction progress of
the ZrIV metal-assisted hydrolysis of sphingomyelin with four timepoints.
Metal
Zr

IV

Triton
X-100
(mM)
0

Temp.
(°°C)

Time
(h)

37

0
4
8
20
0
4
8
20
0
4
8
20
0
4
8
20
0
4
8
20
0
4
8
20

60

2

37

60

16

37

60

Percentage Hydrolysis Percentage Hydrolysis at
pH 7
at pH 4.8
Avg. ± SD %

Avg. ± SD %

0.00 ≤ 0.00
0.12 ≤ 0.01
0.17 ≤ 0.01
0.19 ≤ 0.01
0.00 ≤ 0.00
0.43 ≤ 0.02
0.23 ≤ 0.01
0.51 ≤ 0.03
0.00 ≤ 0.00
0.11 ≤ 0.01
0.24 ≤ 0.01
0.38 ≤ 0.02
0.00 ≤ 0.00
0.65 ≤ 0.03
0.91 ≤ 0.05
3.44 ≤ 0.17
0.00 ≤ 0.00
0.38 ≤ 0.02
0.55 ≤ 0.03
0.78 ≤ 0.04
0.00 ≤ 0.00
1.77 ≤ 0.09
2.95 ≤ 0.15
8.54 ≤ 0.43

0.00 ≤ 0.00
0.06 ≤ 0.00
0.13 ≤ 0.01
0.10 ≤ 0.01
0.00 ≤ 0.00
0.21 ≤ 0.01
0.42 ≤ 0.02
0.81 ≤ 0.04
0.00 ≤ 0.00
0.27 ≤ 0.01
0.29 ≤ 0.01
0.24 ≤ 0.01
0.00 ≤ 0.00
0.28 ≤ 0.01
0.55 ≤ 0.03
2.02 ≤ 0.10
0.00 ≤ 0.00
0.31 ≤ 0.02
0.55 ≤ 0.03
0.61 ≤ 0.03
0.00 ≤ 0.00
1.01 ≤ 0.05
2.00 ≤ 0.10
7.89 ≤ 0.39

115

Table 3.9. The percentage hydrolysis by phosphate concentrations for the reaction progress of
the CeIV metal-assisted hydrolysis of sphingomyelin with four timepoints.
Metal

CeIV

Triton
X-100
(mM)
0

Temp.
(°°C)
37

60

2

37

60

16

37

60

Time
(h)

Percentage Hydrolysis Percentage Hydrolysis
at pH 7
at pH 4.8

0
4
8
20
0
4
8
20
0
4
8
20
0
4
8
20
0
4
8
20
0
4
8
20

Avg. ± SD %
0.00 ≤ 0.0
0.07 ≤ 0.0
0.24 ≤ 0.66
5.84 ≤ 0.54
0.00 ≤ 0.0
14.1 ≤ 1.9
21.1 ≤ 1.5
37.6 ≤ 2.1
0.00 ≤ 0.0
1.22 ≤ 0.33
3.35 ≤ 0.29
7.18 ≤ 0.84
0.00 ≤ 0.0
16.5 ≤ 0.88
36.3 ≤ 3.0
96.2 ≤ 5.3
0.00 ≤ 0.0
4.85 ≤ 0.62
9.21 ≤ 0.59
19.6 ≤ 2.6
0.00 ≤ 0.0
33.5 ≤ 1.8
45.9 ≤ 5.6
60.4 ≤ 2.6

Avg. ± SD %
0.00 ≤ 0.0
1.35 ≤ 0.21
1.26 ≤ 0.23
5.36 ≤ 0.86
0.00 ≤ 0.0
11.2 ≤ 2.0
14.4 ≤ 0.55
38.3 ≤ 1.8
0.00 ≤ 0.00
3.11 ≤ 0.77
3.64 ≤ 0.01
10.2 ≤ 1.0
0.00 ≤ 0.0
18.0 ≤ 1.3
23.5 ≤ 0.45
74.5 ≤ 11
0.00 ≤ 0.00
7.08 ≤ 0.87
8.39 ≤ 0.70
16.9 ≤ 3.5
0.00 ≤ 0.0
21.3 ≤ 1.5
28.2 ≤ 0.15
35.1 ≤ 0.28
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Table 3.10. Estimated half-lives (t1/2) calculated from ZrIV and CeIV hydrolysis of sphingomyelin
at 60 °C or 37 °C from the total phosphocholine plus choline hydrolysis yield percentage or the
choline-only yield percentage. “nd” signifies “not determined”.
Estimated t1/2 (h)
Metal

Zr

IV

Triton
X-100
(mM)
0

Temperature

60 °C

2
16
CeIV

0
2
16

ZrIV

0
2
16

CeIV

0
2
16

37 °C

Avg. pH

4.84
7.03
4.89
7.06
4.89
7.07
4.72
6.95
4.86
7.01
4.75
7.02
4.89
7.04
4.90
7.06
4.90
7.06
4.78
7.02
4.80
7.04
4.86
7.06

Total phosphocholine
plus choline

Choline

Avg. ± SD
300 ≤ 1
200 ≤ 1
24 ≤ 1
33 ≤ 1
8 ≤ 0.5
7 ≤ 0.5
9≤1
19 ≤ 1
5≤1
14 ≤ 1
6 ≤ 0.2
11 ≤ 0.2
3500≤ 4
7000 ≤ 2
800 ≤ 2
1200 ≤ 1
100 ≤ 1
350 ≤ 1
80 ≤ 1
80 ≤ 1
40 ≤ 1
50 ≤ 1
26 ≤ 1
20 ≤ 1

Avg. ± SD
433 ≤ 1
267 ≤ 1
30 ≤ 1
41 ≤ 1
14 ≤ 1
11 ≤ 0.3
10 ≤ 0.2
21 ≤ 0.3
6 ≤ 0.1
14 ≤ 0.2
6 ≤ 0.2
13 ≤ 0.2
nd
nd
800 ≤ 1
nd
150 ≤ 1
400 ≤ 1
60≤ 1
100 ≤ 1
50 ≤ 1
40 ≤ 1
25 ≤ 1
20 ≤ 1
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Figure 3.23. MALDI mass spectra showing the ZrIV-assisted hydrolysis of phosphocholine
with the increasing choline intensity at m/z 104. Spectra represent three different timepoints
in the reaction at 0, 5, and 23 h. Samples prepared with 2 mM phosphocholine, 10 mM ZrCl4,
20 mM TRIS, pH 4.8 were reacted at 60 °C, and then analyzed with MALDI-ToF
instrumentation with DHB matrix in positive ion mode.
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The zirconocene dichloride and non-metal experiments showed 0.05 to 0.12 pH drifts at 60 °C
and -0.02 to 0.07 at 37 °C. The CeIV experiments showed pH drifts in the range of 0.08 to 0.10 at
60 °C and -0.01 to 0.03 at 37 °C which is considerably less than the corollary pH 4.8
experiments. The phosphocholine hydrolysis showed slight pH drifts at 0.05 pH units at 60 °C.
The HEPES experiments demonstrate good pH control during the metal-assisted experiments.
Method validation.
Procedures using positive controls were performed to confirm that the experimental
protocols are able to produce accurate results. The positive controls are compounds that are
expected to give positive results because of their known reactivity with either the colorimetric
reagents or the enzymatic reactions in the various assays. A known quantity of these compounds
was used in similar hydrolysis reactions and/or assay quantification protocols as the hydrolysis
samples, and their observed results were recorded as recovery percentages that were used for
statistical assessment and not correction factors since the recoveries are vial-specific. The
Amplex Red assay quantification results of the positive controls of phosphocholine, choline,
hydrogen peroxide, and the malachite green assay quantification results of inorganic phosphate
levels are tabulated in Tables 3.12 and 3.13 for method validation. These results were evaluated
to determine the validity and scientific significance of not only the established protocols of the
Amplex Red assay and the malachite green assay, but the novel modified choline-only assay
using the Amplex Red kit. The results for the 0 h and 20 h aliquots are shown separately to
evaluate the effect of the experimental duration on the quantification. The positive controls were
quantified by either the total phosphocholine plus choline assay where the enzyme mixture
contained alkaline phosphatase or the choline-only assay where the enzyme mixture did not
contain alkaline phosphatase.
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The differences in metal, buffer, experimental time, and total phosphocholine plus
choline yields vs. choline-only yields were noted. The recoveries of samples with zirconium(IV)
metal were more accurate than the samples with cerium(IV) since the averages for zirconium(IV)
were 98.4% (phosphocholine substrate, total phosphocholine plus choline analysis, 20 mM
piperazine, 20h), 101.7% and 100.3% (choline substrate, total phosphocholine plus choline
analysis, 20 mM piperazine, 0 and 20 h, respectively), 96.6% and 99.7% (choline substrate,
choline-only analysis, 20 mM piperazine, 0 and 20 h, respectively). The recoveries for
cerium(IV) metal were greater than the calculated value since the averages for cerium(IV) were
114.6% and 112.0% (phosphocholine substrate, total phosphocholine plus choline analysis, 20
mM piperazine, 0 and 20 h, respectively), 113.4% (phosphocholine substrate, total
phosphocholine plus choline analysis, 20 mM HEPES, 20 h), 118.4% and 119.8% (choline
substrate, total phosphocholine plus choline analysis, pH 4.8, 0 h and 20 h), 118.6% and 123.6 %
(choline substrate, choline-only analysis, pH 4.8, 0 h and 20 h), and 123.4% and 127.4% (choline
substrate, total phosphocholine and choline analysis, pH 7, 0 h and 20 h).
The hydrogen peroxide positive controls provided by the manufacturer with the assay
were prepared in pure reaction buffer without the presence of experimental metal and buffer
concentrations. The recovery percentages for three different amounts averaged 69.5 ≤ 1.8 % of
the calculated value. Since the peroxide positive controls were prepared from new vials and fresh
dilutions to optimize the recoveries, the poor recovery results indicate that the hydrogen peroxide
positive controls are unacceptable for method validation purposes.
Table 3.13 shows the method validation statistics for the phosphate determinations from
the malachite green assay. The expected phosphate concentration and the observed concentration
calculated from the standard curves for each metal are shown with the recovery percentage. The
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phosphate levels determined from the phosphocholine show 33.0% and 33.2% recoveries for
ZrIV and CeIV-assisted hydrolysis of 1.116 mM phosphocholine in the presence of 10 mM metal,
20 mM piperazine at 60 °C for 20 h which is substantially lower than the theoretical value. The
choline which contains no hydrolysable phosphate shows the expected 0.00% recovery for the
CeIV-assisted hydrolysis of 1.49 mM choline in the presence of 10 mM CeIV and 20 mM
piperazine at 60 °C for 20 h. The hydrolysis percentages calculated from the phosphate
concentrations were compared to the corresponding hydrolysis percentages calculated from the
Amplex Red assay. Two comparisons were taken from Table 3.3 and Table 3.4. For CeIV (2
mM Triton X-100, pH 4.8), the hydrolysis percentages were 70.7 ≤ 7.1% and 81.2 ≤ 5.8% for
phosphate and total phosphocholine plus choline assays, respectively, which is in good
agreement. However, for ZrIV (16 mM, pH 4.8), the hydrolysis percentages were 11.3 ≤ 2.2%
and 73.0 ≤ 7.6% for phosphate and total phosphocholine plus choline assays, respectively, which
is not in good agreement. The recoveries of the positive controls can not be strictly correlated to
the hydrolysis percentages of the sphingomyelin by phosphate concentration because of more
than one dephosphorylation pathway, e.g. phosphate from released phosphocholine or
phosphoceramide. Also, the phosphate used for the preparation of the standard curves did not
undergo the same 20 h heat treatment at 37 °C or 60 °C as that the hydrolysis samples or the
method validation positive controls.
Conclusions.
The ability of a select group of metals to hydrolyze the phosphate ester bond of
sphingomyelin has been demonstrated at two pH values which represent lysosomal and cytosolic
pH conditions and two temperatures of 37 °C and 60 °C which are at or above the gel-liquid
transition of sphingomyelin. Out of the 12 metals salts tested, the metals with the highest
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reactivity are the tetravalent metals CeIV, ZrIV, and HfIV, and the divalent PdII. This can be
predicted by the tetravalent metals’ ability to substantially lower the pKa of water. A comparison
of pH 4.8 and 7 yields at 60 °C show that hydrolysis by CeIV is strongly favored at pH 4.8 while
ZrIV and HfIV do not show a strong pH preference according to phosphocholine and choline
product yields. However, the 37 °C data demonstrates that ZrIV hydrolysis of the phosphate ester
bond is enhanced at lysosomal pH compared to cytosolic pH, while the CeIV hydrolysis is not
enhanced at lysosomal pH. This reversal of trends at the two temperatures most likely reflects a
temperature dependence of metal solubilities, kinetics, and liposomal structure. The hydrolytic
yield differences are much lower at 37 ±C compared to 60 °C which reflects the effect of
increasing temperature on reaction rates at 37 °C. Triton X-100 solubilization of sphingomyelin
liposomes induces changes in the vesicle bilayer structure as evidenced by the turbidity and the
altered hydrolytic yields for all metals.
In the presence of 0, 2, and 16 mM Triton X-100 concentrations, according to the turbidity,
sphingomyelin corresponds to distinctly different structures which are attributed to vesicles (0
mM Triton X-100), mixed vesicle and mixed micelle (2 mM Triton X-100), and mixed micelle
(16 mM Triton X-100) structures. Each of these sphingomyelin populations produced different
metal-assisted hydrolytic yields. The additions of Triton X-100 and/or cholesterol had opposite
effects on the pure sphingomyelin vesicles. The Triton X-100 incorporation increased hydrolytic
yields possibly due to reduced Coloumbic repulsion of the charged headgroups due to Triton X100 interdigitation with concomitant micelle formation. Cholesterol incorporation decreased
hydrolytic yields possibly due to closer packing of the fatty acid chains in the inner sections of
the bilayers which causes a denser outer vesicle shell and less penetration of metal ions.
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Table 3.11. Summary of average pH and DpH values for all metal-assisted experiments.
60 °C
Experimental Conditions
2mM sphingomyelin,
10 mM ZrCl4,
20 mM piperazine
2 mM sphingomyelin,
10 mM HfCl4
20 mM piperazine
2 mM sphingomyelin,
10 mM CeIV ammonium nitrate,
20 mM piperazine
2 mM sphingomyelin,
No metal,
20 mM piperazine
1.116 mM phosphocholine,
10 mM CeIV ammonium nitrate,
20 mM piperazine
2 mM sphingomyelin,
10 mM zirconocene dichloride,
20 mM piperazine
2 mM sphingomyelin,
10 mM ZrCl4,
20 mM HEPES
2 mM sphingomyelin,
10 mM HfCl4
20 mM HEPES
2 mM sphingomyelin,
10 mM CeIV ammonium nitrate,
20 mM HEPES
2 mM sphingomyelin,
No metal,
20 mM HEPES
1.116 mM phosphocholine,
10 mM CeIV ammonium nitrate,
20 mM HEPES
2 mM sphingomyelin,
10 mM zirconocene dichloride,
20 mM HEPES

Triton
X-100
(mM)

Avg pH ± SD

DpH ± SD, n

37 °C
Avg pH ± SD

DpH ± SD, n

0
2
16
0
2
16
0
2
16

4.87 ≤ 0.03
4.86 ≤ 0.03
4.88 ≤ 0.03
4.85 ≤ 0.01
4.83 ≤ 0.01
4.88 ≤ 0.02
4.81 ≤ 0.19
4.73 ≤ 0.02
4.74 ≤ 0.02

0.03 ≤ 0.05, 28
0.02 ≤ 0.03, 30
-0.01 ≤ 0.03, 30
0.01 ≤ 0.00, 10
-0.02 ≤ 0.01, 10
-0.01 ≤ 0.03, 10
0.48 ≤ 0.04, 25
0.42 ≤ 0.04, 27
0.42 ≤ 0.03, 27

4.88 ≤ 0.08
4.90 ≤ 0.04
4.94 ≤ 0.08
na
na
na
4.71 ≤ 0.07
4.86 ≤ 0.10
4.91 ≤ 0.09

0.10 ≤ 0.09, 4
0.04 ≤ 0.04, 4
0.01 ≤ 0.02, 4
na
na
na
0.37 ≤ 0.13, 5
0.29 ≤ 0.07, 6
0.17 ≤ 0.08, 5

0
2
16
0
2
16
0
2
16

4.92 ≤ 0.03
4.91 ≤ 0.02
4.92 ≤ 0.05
4.69 ≤ 0.06
na
na
4.86 ≤ 0.12
4.88 ≤ 0.09
4.94 ≤ 0.08

-0.09 ≤ 0.09, 9
-0.06 ≤ 0.08, 9
-0.12 ≤ 0.06, 17
0.53 ≤ 0.07, 18
na
na
0.10 ≤ 0.10, 7
0.07 ≤ 0.08, 9
0.10 ≤ 0.08, 9

4.95 ≤ 0.16
4.93 ≤ 0.09
4.89 ≤ 0.13
na
na
na
4.93 ≤ 0.06
4.95 ≤ 0.04
5.01 ≤ 0.05

-0.03 ≤ 0.13, 4
-0.05 ≤ 0.06, 4
-0.09 ≤ 0.14, 4
na
na
na
-0.01 ≤ 0.08, 5
0.03 ≤ 0.04, 6
0.04 ≤ 0.05, 4

0
2
16
0
2
16

7.05 ≤ 0.02
7.05 ≤ 0.01
7.06 ≤ 0.03
7.10 ≤ 0.01
7.07 ≤ 0.00
7.10 ≤ 0.01

0.02 ≤ 0.01, 26
0.01 ≤ 0.01, 28
-0.03 ≤ 0.03, 28
0.02 ≤ 0.01, 10
0.00 ≤ 0.00, 9
-0.03 ≤ 0.02, 10

7.02 ≤ 0.05
7.07 ≤ 0.04
7.05 ≤ 0.07
na
na
na

0.03 ≤ 0.07, 5
-0.05 ≤ 0.04, 5
-0.05 ≤ 0.09, 5
na
na
na

0

7.00 ≤ 0.05

0.10 ≤ 0.04, 24

7.05 ≤ 0.06

0.03 ≤ 0.11, 5

2
16
0
2
16
0
2
16
0
2
16

7.02 ≤ 0.03
7.03 ≤ 0.01
7.08 ≤ 0.14
7.16 ≤ 0.12
7.07 ≤ 0.12
7.08 ≤ 0.08
na
na
7.03 ≤ 0.06
6.98 ≤ 0.07
6.99 ≤ 0.06

0.10 ≤ 0.04, 26
0.08 ≤ 0.04, 26
0.12 ≤ 0.01, 9
0.07 ≤ 0.11, 10
0.05 ≤ 0.10, 16
0.05 ≤ 0.04, 14
na
na
0.08 ≤ 0.14, 6
0.06 ≤ 0.09, 9
0.06 ≤ 0.09, 7

7.08 ≤ 0.01
7.08 ≤ 0.12
6.99 ≤ 0.10
7.05 ≤ 0.08
7.01 ≤ 0.08
na
na
na
7.04 ≤ 0.05
7.01 ≤ 0.07
7.01 ≤ 0.11

0.01 ≤ 0.08, 5
-0.01 ≤ 0.09, 5
0.06 ≤ 0.24, 4
0.00 ≤ 0.1, 5
-0.02 ≤ 0.09, 4
na
na
na
0.07 ≤ 0.12, 5
0.05 ≤ 0.12, 6
0.05 ≤ 0.09, 4

∆pH = initial reaction pH at t = 0 h minus final reaction pH at t = 20 h;
na = not available; n = number of trials
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Table 3.12. Summary of the positive control results used in the Amplex® Red assay method validation.c
Positive
Control

Sample

Parameters

t=0h
Phosphocholine

Cholineb

Total phosphocholine
and cholinea
t = 20 h

t=0h

t = 20 h

1.116 mM phosphocholine, Calculated concentration (mM)
1.12 mM
1.12 mM
1.116 mM
0 mM
10 mM ZrCl4,
0.888
Observed concentration (mM) ≤ SD 0.980 ≤ 0.11 1.10 ≤ 0.29
0.039 ≤ 0.61
3
20 mM piperazine, pH 4.8, n
4
3
2
79.6 %
Recovery %
87.8%
3.50 %
98.4 %
60 °C, 20 h
Phosphocholine 1.116 mM phosphocholine, Calculated Concentration (mM)
1.12 mM
1.12 mM
1.12 mM
1.12 mM
10 mM CeIV ammonium
1.19 ≤ 0.26
Observed concentration (mM) ≤ SD 1.28 ≤ 0.23
1.25 ≤ 0.25
0.213 ≤ 0.04
3
4
nitrate,
n
5
5
19.09 %
20 mM piperazine, pH 4.8, Recovery %
114.6 %
112.0 %
106.5 %
60 °C, 20 h
1.12 mM
1.12 mM
1.12 mM
Phosphocholine 1.116 mM phosphocholine, Calculated Concentration (mM)
1.12 mM
10 mM CeIV ammonium
1.26 ≤ 0.18
0.290 ≤ 0.13
Observed concentration (mM) ≤ SD 1.15 ≤ 0.16
1.17 ≤ 0.06
nitrate,
n
4
4
3
3
20 mM HEPES, pH 7, 60 Recovery %
103.4 %
113.4 %
26.0 %
105.0 %
°C, 20 h
Choline
1.116 mM phosphocholine, Calculated Concentration (mM)
1.49 mM
1.49 mM
1.49 mM
1.49 mM
10 mM ZrCl4,
1.49
Observed concentration (mM) ≤ SD 1.52
1.44 ≤ 0.08
1.49 ≤ 0.09
20 mM piperazine, pH 4.8, n
2
2
3
4
96.6 %
99.7 %
Recovery %
101.7 %
100.3 %
60 °C, 20 h
Choline
1.116 mM phosphocholine, Calculated Concentration (mM)
1.49 mM
1.49 mM
1.49 mM
1.49 mM
10 mM CeIV ammonium
1.79 ≤ 0.20
1.77 ≤ 0.31
1.84 ≤ 0.30
Observed concentration (mM) ≤ SD 1.76 ≤ 0.17
nitrate,
n
5
5
4
4
118.4 %
119.8 %
118.6 %
123.6 %
20 mM piperazine, pH 4.8, Recovery %
60 °C, 20 h
a
The total phosphocholine and choline amount is calculated from the Amplex Red assay where alkaline phosphatase enzyme was included in the
reactive mix. Results include the phosphocholine and choline substrate present in the hydrolysis reaction. Metals included ZrCl4 or cerium(IV) ammonium
nitrate. Buffers included either piperazine, pH 4.8, or HEPES, pH 7.0.
b
The choline amount is the amount calculated from the Amplex Red assay where alkaline phosphatase enzyme was omitted in the reactive mix. Results
include only the choline substrate present in the hydrolysis reaction.
c
“na” = not available, n = number of samples
d
The hydrogen peroxide samples were prepared immediately prior to the assay preparation and not a metal-assisted hydrolysis reaction.
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Continued Table 3.12.: Summary of the positive control results used in the Amplex® Red assay method validation.c
Positive
Control

Choline

H2O2

Sample

1.116 mM phosphocholine,
10 mM CeIV ammonium
nitrate, 20 mM HEPES, pH
7, 60 °C, 20 h
Reaction bufferd
(Tris, MgCl),
37 °C

H2O2

Reaction bufferd
(Tris, MgCl)
37 °C

H2O2

Reaction bufferd
(Tris, MgCl)
37 °C

a

Parameters

Calculated Concentration (mM)
Observed concentration (mM) ≤ SD
n
Recovery %
Calculated Concentration (mM)
Observed concentration (mM)
n
Recovery %
Calculated Concentration (mM)
Observed concentration (mM)
n
Recovery %
Calculated Concentration (mM)
Observed concentration (mM)
n
Recovery %

Cholineb

Total phosphocholine
and cholinea
t=0h

t = 20 h

t=0h

t = 20 h

1.49 mM
1.84 ≤ 0.12
3
123.4 %
0.022 mM
0.015
2
68.2 %
0.044 mM
0.031
2
71.6 %
na

1.49 mM
1.90 ≤ 0.23
3
127.4 %
na

1.49 mM
1.68
2
112.6 %
na

1.49 mM
1.76
2
117.8 %
na

na

na

na

na

0.066 mM
0.045
2
68.8 %

na

The total phosphocholine and choline amount is calculated from the Amplex Red assay where alkaline phosphatase enzyme was included
in the reactive mix. Results include the phosphocholine and choline substrate present in the hydrolysis reaction. Metals included ZrCl4 or
cerium(IV) ammonium nitrate. Buffers included either piperazine, pH 4.8, or HEPES, pH 7.0.
b
The choline amount is the amount calculated from the Amplex Red assay where alkaline phosphatase enzyme was omitted in the reactive
mix. Results include only the choline substrate present in the hydrolysis reaction.
c
“na” = not available, n = number of samples
d
The hydrogen peroxide samples were prepared immediately prior to the assay preparation and not a metal-assisted hydrolysis reaction.
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Table 3.13. Summary of the positive control results used in the malachite green assay method validation.
Positive Control

Sample Description

Parameter

Inorganic Phosphate
t = 20 h - 0 h

Phosphocholine

Phosphocholine

Phosphocholine

Choline

Choline

n = number of trials

1.116 mM phosphocholine,
10 mM ZrCl4, 20 mM
piperazine, pH 4.8, 60 °C, 20 h

Calculated concentration (µM)
Observed concentration (µM) ≤ SD
n
Recovery %
1.116 mM phosphocholine,
Calculated concentration (µM)
10 mM metal CeIV ammonium
Observed concentration (µM) ≤ SD
nitrate, 20 mM piperazine, pH
n
Recovery %
4.8, 60 °C, 20 h
1.116 mM phosphocholine,
Calculated concentration (µM)
10 mM metal CeIV ammonium
Observed concentration (µM) ≤ SD
nitrate, 20 mM HEPES, pH 7, 60 n
Recovery %
°C, 20 h
1.490 mM choline,
Calculated Concentration (µM)
10 mM metal (CeIV ammonium
Observed concentration (µM) ≤ SD
nitrate), 20 mM piperazine, pH
n
4.8, 60 °C, 20 h
Recovery %
1.490 mM choline,
Calculated Concentration (µM)
10 mM metal (CeIV ammonium
Observed concentration (µM) ≤ SD
nitrate), 20 mM HEPES, pH 7,
n
60 °C, 20 h
Recovery %

1120 uM
370 uM
2
33.0 %
1120 uM
372 uM ≤ 117
4
33.2 %
1120 uM
447 uM ≤ 307
3
39.9 %
0 uM
-9.04 uM
2
< 0.00 %
0 uM
16.02 uM
2
>0.00%
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The evaluation of ZrIV-assisted metal hydrolysis of sphingomyelin as a possible therapeutic
reagent in Niemann-Pick diseases Type A and B is confirmed because the hydrolysis is increased
at lysosomal pH at physiological temperatures of 37 °C. The cellular toxicity of metals which
are used as therapeutic agents must be taken into account, and zirconium(IV) metal is non-toxic
while cerium(IV) is toxic whose effects including liver damage may be better understood in
terms of cerium(IV)’s ability to hydrolyze the phosphate ester bond in sphingomyelin.
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CHAPTER IV CONCLUSIONS.

Peptide hydrolysis.

We have described in the first chapter the potential uses for metal-assisted hydrolysis of
the peptide bond or the phosphate ester bond for potential therapeutic and proteolytic use. In the
second chapter, we have described the unique application of ZrIV-assisted hydrolysis of the
peptide bond of a biologically-active protein using a metal-azacrown ether complex. By using
HPLC-ESI-MS and MS/MS, and MALDI-TOF MS, we have demonstrated that ZrIV/4, 13-diaza18-crown-6 facilitates hydrolysis of the 30-mer oligopeptides oxidized bovine insulin chain B at
pH 7.0 and 60 °C. The ZrIV-assisted hydrolysis of insulin chain B demonstrated that not only
does the ZrIV have amino acid side chain specificity, but that it hydrolyzes in good yields. Using
the extensive characterization of the hydrolysis products by Findpept software and MS/MS mass
spectral techniques, we were able to discover that the ZrIV in the presence of the azacrown ether
hydrolyzes not only at oxophilic, negatively-charged amino acids as predicted by earlier
dipeptide work, but also possesses an unprecedented specificity toward cysteine sulfonic acid
which is a distinctive marker for protein oxidative stress. This may be a useful metalloprotease
for proteolytic studies which focus on the effect of oxidative stress on proteins.
In our analysis of the hydrolysis products, apparent major levels of cleavage were
produced at Gly8-Ser9, Gly20-Glu21, Ser9-His10, Cys(SO3H)7-Gly8 and Cys(SO3H)19-Gly20
sequences which indicates three hydrolytic specificities, namely, cysteine sulfonic acids,
negatively-charged, sequential Gly-Glu, and a Gly-Ser-His motif which contains an oxygencontaining sidechain. Given the association of cysteine sulfonic acids in proteins that have

132

undergone oxidative stress such as those found in amyloid fibril formation, Parkinson’s disease,
and other physiological processes, the therapeutic potential in the hydrolysis of these
irreversibly-oxidized amino acids to prevent possible misfolding is promising.Two minor side
reactions were also characterized in order to monitor any peptide product modifications. It was
found that the ZrIV/4,13-diaza-18-crown-6 complex promotes lactamization of the N-terminal
Glu21 and deamidation of Asn3 and Gln4.
Phospholipid hydrolysis.
The development of ZrIV and other non-toxic metal complexes for therapeutic treatment
of patients with Niemann-Pick Disease and other lysosomal storage disorders is a very novel,
promising area of research. We first analyzed a group of metals, described in Chapter III, which
included transition metals and lanthanides with demonstrated ability to hydrolyze the phosphate
ester bond in synthetic compounds. While the ZrIV does not have significant cellular toxicity and
has potential therapeutic use, the toxic effects of CeIV through phosphate ester hydrolytic
pathways may be elucidated through this study. Two different assays were chosen for
quantification of yields including the malachite green assay which quantitates inorganic
phosphate and the Amplex-Red assay which measures the total phosphocholine plus choline
yields. The novel adaptation of this Amplex-Red assay by inclusion of a choline-specific
enzymatic reaction using similar reagents with selective omission of the alkaline phosphatase
enzyme produced corollary results that allowed quantification and comparison of both the
phosphocholine and the choline yields. This differentiation between phosphocholine and choline
yields allows direct assessment of the regioselectivity of the metal-assisted hydrolysis of the
phosphate ester bond of sphingomyelin in order to compare with the physiological enzymatic
hydrolysis by acid sphingomyelinase in the lysosomes which yields exclusively phosphocholine
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product plus a ceramide that proceeds as a second messenger to downstream signal transduction
cascades. The data show that tetravalent metals ZrIV, CeIV, and HfIV and the divalent PdII
hydrolyze the phosphate ester bond in sphingomyelin in high yields. The solubilization of pure
sphingomyelin vesicles to mixed micelles and/or pure micelles by the addition of Triton X-100
surfactant increased hydrolysis rates. Estimated half-lives of CeIV and ZrIV for pure
sphingomyelin liposomes with Triton X-100 solubilization at 60 °C are 5.06 h and 6.50 h,
respectively. All hydrolysis experiments were run in parallel at two pH values which represent
lysosomal pH 4.8 and cytosolic pH 7 in order to assess the increase in hydrolysis of the
phosphate ester bond, and thus enzymatic mimicry, at lysosomal pH relative to cytosolic pH. We
have shown that ZrIV-assisted hydrolysis of pure sphingomyelin liposomes at 37 °C is
significantly enhanced at pH 4.8 compared to pH 7 in micellar form.

Experiments with

cholesterol effects on sphingomyelin liposomes demonstrate that the dense packing effects of
cholesterol decrease the hydrolysis rates. Overall, we have demonstrated metal-assisted
hydrolysis of a major, physiological phospholipid to yield non-cytotoxic products of
phosphocholine and choline.

